JPH01258684A - 3-substituted quinolinium thiomethylcephalosporin derivative - Google Patents
3-substituted quinolinium thiomethylcephalosporin derivativeInfo
- Publication number
- JPH01258684A JPH01258684A JP63086036A JP8603688A JPH01258684A JP H01258684 A JPH01258684 A JP H01258684A JP 63086036 A JP63086036 A JP 63086036A JP 8603688 A JP8603688 A JP 8603688A JP H01258684 A JPH01258684 A JP H01258684A
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- substituted lower
- formula
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 3-substituted quinolinium Chemical class 0.000 title abstract description 99
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 22
- 125000005843 halogen group Chemical group 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000000524 functional group Chemical group 0.000 claims abstract description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract description 4
- 125000006239 protecting group Chemical group 0.000 claims description 22
- 125000003277 amino group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 10
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 3
- 125000003118 aryl group Chemical group 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 238000007126 N-alkylation reaction Methods 0.000 abstract 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000001780 cephalosporins Chemical class 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 229940124587 cephalosporin Drugs 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000005236 alkanoylamino group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- XQNIYBBHBZAQEC-UHFFFAOYSA-N diphosphorus trisulphide Chemical compound S=PSP=S XQNIYBBHBZAQEC-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical compound O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- UHFHXGARFLWEAF-UHFFFAOYSA-N 1-methylquinoline-4-thione Chemical compound C1=CC=C2N(C)C=CC(=S)C2=C1 UHFHXGARFLWEAF-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- QYVUOGJABIKMCZ-UHFFFAOYSA-N 1-sulfanylquinolin-1-ium Chemical compound S[N+]1=CC=CC2=CC=CC=C12 QYVUOGJABIKMCZ-UHFFFAOYSA-N 0.000 description 1
- KXZSVYHFYHTNBI-UHFFFAOYSA-N 1h-quinoline-2-thione Chemical compound C1=CC=CC2=NC(S)=CC=C21 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- FVTWJXMFYOXOKK-UHFFFAOYSA-N 2-fluoroacetamide Chemical group NC(=O)CF FVTWJXMFYOXOKK-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- SEUSIPHENXRHAC-UHFFFAOYSA-N 2-methyl-3h-quinoline-4-thione Chemical compound C1=CC=C2C(=S)CC(C)=NC2=C1 SEUSIPHENXRHAC-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- WUJMXRUCXSUCII-LRTDYKAYSA-N C(C1=CC=CC=C1)(C1=CC=CC=C1)OC(=O)C1=CC(S[C@H]2N1C(C2)=O)CI Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)OC(=O)C1=CC(S[C@H]2N1C(C2)=O)CI WUJMXRUCXSUCII-LRTDYKAYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- KYHBLDMJXVGVKJ-UHFFFAOYSA-N benzenecarbothioic acid S-(5-quinolinyl) ester Chemical compound C=1C=CC2=NC=CC=C2C=1SC(=O)C1=CC=CC=C1 KYHBLDMJXVGVKJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- PZHAYLDNAVHZCP-UHFFFAOYSA-N benzhydryl 2-chloroacetate Chemical compound C=1C=CC=CC=1C(OC(=O)CCl)C1=CC=CC=C1 PZHAYLDNAVHZCP-UHFFFAOYSA-N 0.000 description 1
- GKFUHVPOGCXIJW-UHFFFAOYSA-N benzhydryl 2-iodoacetate Chemical compound C=1C=CC=CC=1C(OC(=O)CI)C1=CC=CC=C1 GKFUHVPOGCXIJW-UHFFFAOYSA-N 0.000 description 1
- UUZYBYIOAZTMGC-UHFFFAOYSA-M benzyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC1=CC=CC=C1 UUZYBYIOAZTMGC-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- DXVOSTCYXXRQEW-UHFFFAOYSA-N iodocyclobutane Chemical compound IC1CCC1 DXVOSTCYXXRQEW-UHFFFAOYSA-N 0.000 description 1
- PCEBAZIVZVIQEO-UHFFFAOYSA-N iodocyclopentane Chemical compound IC1CCCC1 PCEBAZIVZVIQEO-UHFFFAOYSA-N 0.000 description 1
- VLODBNNWEWTQJX-UHFFFAOYSA-N iodocyclopropane Chemical compound IC1CC1 VLODBNNWEWTQJX-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 125000005646 oximino group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
及呈よ二亘朋更更
本発明は医療の分野において、細菌感染症の治療剤とし
て有用な新規なセファロスポリン誘導体に関するもので
ある。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel cephalosporin derivative useful in the medical field as a therapeutic agent for bacterial infections.
更来曳玖亙
従来、セファロスポリン系抗生物質は、人及び動物の病
原性細菌の感染により生ずる疾患の治療に広く利用され
ており、例えばペニシリン系抗生物質に対して耐性を有
する細菌の感染による疾患の治療に特に有用であり、加
えて毒性も低いことから安全性の面でもセファロスポリ
ン表抗生物質はすぐれている。このような背景から、抗
菌力より強くかつ安全性の面ですぐれたセファロスポリ
ン系抗生物質を創製しようとする試みが非常に多くなさ
れている。Previously, cephalosporin antibiotics have been widely used to treat diseases caused by infection with pathogenic bacteria in humans and animals, such as infections caused by bacteria resistant to penicillin antibiotics. Cephalosporin antibiotics are particularly useful in the treatment of diseases caused by cephalosporins, and have low toxicity, making them excellent in terms of safety. Against this background, many attempts have been made to create cephalosporin antibiotics that have stronger antibacterial activity and are superior in terms of safety.
このような試みのうち、セファロスポリン核の3位の置
換基として、複素環チオメチル基を有する化合物は数多
く知られている。例えば、5−(1−メチル−111−
テトラゾリル)チオメチル基を有するものとして一般名
セフメノキシム、セフビラミド及びセフビラミド等が、
又、2−(5−メチル−1,3゜4−チアジアゾリル)
チオメチル基を有するものとして一般名セファゾリンが
、又、5−[1−(2−ジメチルアミノエチル)−LH
−テトラゾリルコチオメチル基を有するものとして一般
名セフオチアム等が挙げられる。しかしながら、3位に
置換キノリニウムチオメチル基を有する化合物は全く知
られていない。Among such attempts, many compounds having a heterocyclic thiomethyl group as a substituent at the 3-position of the cephalosporin nucleus are known. For example, 5-(1-methyl-111-
Those having a (tetrazolyl)thiomethyl group include the generic names cefmenoxime, cefviramide, cefviramide, etc.
Also, 2-(5-methyl-1,3゜4-thiadiazolyl)
The common name cefazolin as having a thiomethyl group is also known as 5-[1-(2-dimethylaminoethyl)-LH
Examples of compounds having a -tetrazolylcothiomethyl group include the common name cefothiam. However, no compound having a substituted quinolinium thiomethyl group at the 3-position is known.
発明が解決しようとする課題
病原性細菌に対して、すぐれた抗菌活性を示しかつ安全
性の面でもすぐれた性質を有する化合物を提供せんとす
るものである。Problem to be Solved by the Invention It is an object of the invention to provide a compound that exhibits excellent antibacterial activity against pathogenic bacteria and has excellent safety properties.
課題を解゛するための手
本発明者らは、すぐれた抗菌活性を有しかつ安全性のす
ぐれたセファロスポリン誘導体を創製するべく鋭意研究
した結果、セファロスポリン核の3位に置換キノリニウ
ムチオメチル基を有する新規なセファロスポリン誘導体
が優れた抗菌活性を有することを見出し1本発明を完成
した。As a result of intensive research to create a cephalosporin derivative with excellent antibacterial activity and excellent safety, the present inventors discovered a substituted compound at the 3-position of the cephalosporin core. The present invention was completed by discovering that a novel cephalosporin derivative having a nolinium thiomethyl group has excellent antibacterial activity.
本発明は、一般代
[式中、R゛は水素原子、置換されていてもよい低級ア
ルキル基、置換されていてもよいシクロアルキル基、置
換されていてもよい低級アルケニル基。The present invention is directed to the general group [wherein R' is a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group].
置換されていてもよい低級アルキニル基、置換されてい
てもよいアリール基又は置換されていてもよいアラルキ
ル基を、R1は置換されていてもよい低級アルキル基、
置換されていてもよいシクロアルキル基、置換されてい
てもよい低級アルケニル基又は置換されていてもよい低
級アルキニル基を、R3、R4及びR゛は同−又は異な
っていてもよく、水素原子、ハロゲン原子、置換されて
いてもよい低級アルキル基、水酸基、低級アルコキシ基
、低級アルカノイルオキシ基、アミノ基、低級アルキル
アミノ基、低級アルカノイルアミノ基、カルボキシル基
、低級アルコキシカルボニル基、置換されていてもよい
カルバモイル基、スルホ基、スルファモイル基、低級ア
ルカノイル基又はニトロ基をそれぞれ示す]で表される
化合物又はその無毒性塩、その製造法及び該化合物を有
効成分する抗菌剤に関する。an optionally substituted lower alkynyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group, R1 is an optionally substituted lower alkyl group,
R3, R4 and R' may be the same or different, and a hydrogen atom, Halogen atom, optionally substituted lower alkyl group, hydroxyl group, lower alkoxy group, lower alkanoyloxy group, amino group, lower alkylamino group, lower alkanoylamino group, carboxyl group, lower alkoxycarbonyl group, even if substituted The present invention relates to a compound represented by a carbamoyl group, a sulfo group, a sulfamoyl group, a lower alkanoyl group, or a nitro group, respectively, or a non-toxic salt thereof, a method for producing the same, and an antibacterial agent containing the compound as an active ingredient.
次に本明細書の記載において言及される、各種用語及び
その適当な例について以下に説明する。Next, various terms and appropriate examples thereof mentioned in the description of this specification will be explained below.
ハロゲン原子とは、フッ素原子、塩素原子、臭素原子又
はヨウ素原子を意味する。A halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
置換されていてもよい低級アルキル基としては、例えば
ハロゲン原子、水酸基、メトキシ基、エトキシ基、プロ
ポキシ基、イソプロポキシ基、フルオロメトキシ基、ジ
フルオロメトキシ基、トリフルオロメトキシ基、ホルミ
ルオキシ基、アセトキシ基、フルオロアセトキシ基、カ
ルバモイル基、N−メチルカルバモイル基、N、N−ジ
メチルカルバモイル基、カルバモイルオキシ基、N−メ
チルカルバモイルオキシ基、N、N−ジメチルカルバモ
イルオキシ基、アミノ基、メチルアミノ基、ジメチルア
ミノ基、ホルムアミド基、アセトアミド基、フルオロア
セトアミド基、カルボキシル基、メトキシカルボニル基
、エトキシカルボニル基、スルホ基、スルファモイル基
、シアノ基、ホルミル基、アセチル基、フルオロアセチ
ル基、メチルチオ基、エチルチオ基、フルオロメチルチ
オ基、1−フルオロエチルチオ基、2−フルオロエチル
チオ基、チアゾリル基、2−アミノチアゾリル基、5−
アミノ−1,2,4−チアジアゾリル基、L、2.3−
チアジアゾリル基、イミダゾリル基、チエニル基、フラ
ニル基、ピリジル基、キノリル基、イソキノリル基、ピ
ペラジニル基、ピロリジニル基及びモルホリニル基等か
らなる群より選ばれる1個若しくはそれ以上の置換基で
置換されていてもよい、例えばメチル基、エチル基、プ
ロピル基、イソプロピル基、ブチル基、イソブチル基、
5ee−ブチル基、tert−ブチル基、ペンチル基又
はヘキシル基等の炭素数1ないし6個のアルキル基が挙
げられる。Examples of the optionally substituted lower alkyl group include a halogen atom, hydroxyl group, methoxy group, ethoxy group, propoxy group, isopropoxy group, fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, formyloxy group, and acetoxy group. , fluoroacetoxy group, carbamoyl group, N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, carbamoyloxy group, N-methylcarbamoyloxy group, N,N-dimethylcarbamoyloxy group, amino group, methylamino group, dimethyl Amino group, formamide group, acetamide group, fluoroacetamide group, carboxyl group, methoxycarbonyl group, ethoxycarbonyl group, sulfo group, sulfamoyl group, cyano group, formyl group, acetyl group, fluoroacetyl group, methylthio group, ethylthio group, fluoro Methylthio group, 1-fluoroethylthio group, 2-fluoroethylthio group, thiazolyl group, 2-aminothiazolyl group, 5-
Amino-1,2,4-thiadiazolyl group, L, 2.3-
Even if it is substituted with one or more substituents selected from the group consisting of thiadiazolyl group, imidazolyl group, thienyl group, furanyl group, pyridyl group, quinolyl group, isoquinolyl group, piperazinyl group, pyrrolidinyl group, morpholinyl group, etc. Good, such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group,
Examples include alkyl groups having 1 to 6 carbon atoms such as 5ee-butyl group, tert-butyl group, pentyl group, and hexyl group.
置換されていてもよいシクロアルキル基としては、例え
ばカルボキシル基、カルバモイル基、アミノ基、メチル
アミノ基、ジメチルアミノ基、スルホ基、水酸基及びシ
アノ基等からなる群より選ばれる1個若しくはそれ以上
の置換基で置換されていてもよい1例えばシクロプロピ
ル基、シクロブチル基、シクロペンチル基又はシクロヘ
キシル基等の炭素数3ないし6個のシクロアルキル基が
挙げられる。Examples of the optionally substituted cycloalkyl group include one or more groups selected from the group consisting of carboxyl group, carbamoyl group, amino group, methylamino group, dimethylamino group, sulfo group, hydroxyl group, cyano group, etc. For example, a cycloalkyl group having 3 to 6 carbon atoms such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group may be substituted with a substituent.
置換されていてもよい低級アルケニル基としては、例え
ばハロゲン原子、カルボキシル基、アミノ基、スルホ基
、水酸基、カルバモイル基及びシアノ基等からなる群よ
り選ばれる1個若しくはそれ以上の置換基で置換されて
いてもよい、例えばビニル基、アリル基、1−プロペニ
ル基、イソプロペニル基、1−ブテニル基、2−ブテニ
ル基、1−ペンテニル基又は1−へキセニル基等の炭素
数2なしい6個のアルケニル基が挙げられる。Examples of the optionally substituted lower alkenyl group include one or more substituents selected from the group consisting of a halogen atom, a carboxyl group, an amino group, a sulfo group, a hydroxyl group, a carbamoyl group, a cyano group, etc. 2 to 6 carbon atoms, such as a vinyl group, an allyl group, a 1-propenyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 1-pentenyl group, or a 1-hexenyl group. Examples include alkenyl groups.
置換されていてもよい低級アルキニル基としては、例え
ばハロゲン原子、水酸基、アミノ基、カルボキシル基、
カルバモイル基、スルホ基及びシアノ基等からなる群よ
り選ばれる1個若しくはそれ以上の置換基で置換されて
いてもよい、例えばエチニル基、1−プロピニル基、プ
ロパルギル基、1−ブチニル基、1−ペンチニル基又は
1−ヘキシニル基等の炭素数2ないし6個のアルキニル
基が挙げられる。Examples of the optionally substituted lower alkynyl group include a halogen atom, a hydroxyl group, an amino group, a carboxyl group,
Optionally substituted with one or more substituents selected from the group consisting of carbamoyl group, sulfo group, cyano group, etc., such as ethynyl group, 1-propynyl group, propargyl group, 1-butynyl group, 1- Examples include alkynyl groups having 2 to 6 carbon atoms such as pentynyl group and 1-hexynyl group.
置換されていてもよいアリール基としては、例えばハロ
ゲン原子、メチル基、エチル基、フルオロメチル基、ト
リフルオロメチル基、アミノメチル基、カルボキシメチ
ル基、カルバモイルメチル基、スルホメチル基、水酸基
、メトキシ基、フルオロメトキシ基、アセトキシ基、ア
ミノ基、メチルアミノ基、ジメチルアミノ基、アセトア
ミド基、カルボキシル基、メトキシカルボニル基、カル
バモイル基、N−メチルカルバモイル基、NlN−ジメ
チルカルバモイル基、カルバモイルオキシ基、スルホ基
、スルファモイル基、シアノ基及びニトロ基等からなる
群より選ばれる1個若しくはそれ以上の置換基で置換さ
れていてもよい1例えばフェニル基又はナフチル基等の
炭素数6ないし10個のアリール基が挙げられる。Examples of the optionally substituted aryl group include a halogen atom, methyl group, ethyl group, fluoromethyl group, trifluoromethyl group, aminomethyl group, carboxymethyl group, carbamoylmethyl group, sulfomethyl group, hydroxyl group, methoxy group, Fluoromethoxy group, acetoxy group, amino group, methylamino group, dimethylamino group, acetamido group, carboxyl group, methoxycarbonyl group, carbamoyl group, N-methylcarbamoyl group, NlN-dimethylcarbamoyl group, carbamoyloxy group, sulfo group, Examples include aryl groups having 6 to 10 carbon atoms such as phenyl groups or naphthyl groups, which may be substituted with one or more substituents selected from the group consisting of sulfamoyl groups, cyano groups, nitro groups, etc. It will be done.
置換されていてもよいアラルキル基としては。As the optionally substituted aralkyl group.
例えばハロゲン原子、メチル基、エチル基、フルオロメ
チル基、トリフルオロメチル基、アミノメチル基、カル
ボキシメチル基、カルバモイルメチル基、スルホメチル
基、水酸基、メトキシ基、フルオロメトキシ基、アセト
キシ基、アミノ基、メチルアミノ基、ジメチルアミノ基
、アセトアミド基、カルボキシル基、メトキシカルボニ
ル基、カルバモイル基、N−メチルカルバモイル基、N
、N−ジメチルカルバモイル基、カルバモイルオキシ基
、スルホ基、スルファモイル基、シアノ基及びニトロ基
等からなる群より選ばれる1個若しくはそれ以上の置換
基で置換されていてもよい、例えばベンジル基、フェネ
チル基又はナフチルメチル基等の炭素数7ないし12個
のアラルキル基が挙げられる。For example, halogen atom, methyl group, ethyl group, fluoromethyl group, trifluoromethyl group, aminomethyl group, carboxymethyl group, carbamoylmethyl group, sulfomethyl group, hydroxyl group, methoxy group, fluoromethoxy group, acetoxy group, amino group, methyl Amino group, dimethylamino group, acetamido group, carboxyl group, methoxycarbonyl group, carbamoyl group, N-methylcarbamoyl group, N
, N-dimethylcarbamoyl group, carbamoyloxy group, sulfo group, sulfamoyl group, cyano group, nitro group, etc., for example, benzyl group, phenethyl group. or an aralkyl group having 7 to 12 carbon atoms such as a naphthylmethyl group.
低級アルコキシ基としては1例えばメトキシ基。Examples of the lower alkoxy group include methoxy group.
エトキシ基、プロポキシ基、イソプロポキシ基、ブトキ
シ基、イソブトキシ基、r、ert−ブトキシ基。Ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, r, ert-butoxy group.
ペンチル・オキシ基、イソペンチルオキシ基又はヘキシ
ルオキシ基等の炭素数1ないし6個からなるアルコキシ
基が挙げられる9
低級アルカノイルオキシ基としては、例えばアセトキシ
基、プロピオニルオキシ基又はイソバレリルオキシ基等
の炭素数1ないし6個からなるアルカノイルオキシ基が
挙げられる。Examples of the lower alkanoyloxy group include alkoxy groups having 1 to 6 carbon atoms such as pentyloxy group, isopentyloxy group, and hexyloxy group.9 Examples of lower alkanoyloxy groups include acetoxy group, propionyloxy group, and isovaleryloxy group. Examples include alkanoyloxy groups having 1 to 6 carbon atoms.
低級アルキルアミノ基としては、例えばメチルアミノ基
、ジメチルアミノ基、エチルアミノ基、ジエチルアミノ
基、プロピルアミノ基、ジイソプロピルアミノ基、ブチ
ルアミノ基、ペンチルアミノ基又はヘキシルアミノ基等
の炭素数1ないし6個の低級アルキル基l又は2個で置
換されたモノアルキルアミノ基又はジアルキルアミノ基
が挙げられる。Examples of lower alkylamino groups include those having 1 to 6 carbon atoms, such as a methylamino group, dimethylamino group, ethylamino group, diethylamino group, propylamino group, diisopropylamino group, butylamino group, pentylamino group, or hexylamino group. A monoalkylamino group or a dialkylamino group substituted with one or two lower alkyl groups may be mentioned.
低級アルカノイルアミノ基としては、例えばホルムアミ
ド基、アセトアミド基、プロピオニルアミノ基、ブチリ
ルアミノ基、ペンタノイルアミノ基又はヘキサノイルア
ミノ基等の炭素数1ないし6個からなるアルカノイルア
ミノ基が挙げられる。Examples of the lower alkanoylamino group include alkanoylamino groups having 1 to 6 carbon atoms, such as a formamide group, an acetamido group, a propionylamino group, a butyrylamino group, a pentanoylamino group, or a hexanoylamino group.
低級アルコキシカルボニル基としては、例えばメトキシ
カルボニル基、エトキシカルボニル基、インプロポキシ
カルボニル基、ブトキシカルボニル基、ペンチルオキシ
カルボニル基又はヘキシルオキシカルボニル基等の炭素
数2ないし7個からなるアルコキシカルボニル基が挙げ
られる。Examples of the lower alkoxycarbonyl group include alkoxycarbonyl groups having 2 to 7 carbon atoms such as methoxycarbonyl group, ethoxycarbonyl group, impropoxycarbonyl group, butoxycarbonyl group, pentyloxycarbonyl group, or hexyloxycarbonyl group. .
低級アルカノイル基としては、例えばホルミル基、アセ
チル基、プロピオニル基、ブチリル基、イソブチリル基
、ピバロイル基又はヘキサノイル基等の炭素数1ないし
6個のアルカノイル基が挙げられる。Examples of the lower alkanoyl group include alkanoyl groups having 1 to 6 carbon atoms such as formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, pivaloyl group, and hexanoyl group.
置換されて・いてもよいカルバモイル基としては。Examples of carbamoyl groups that may be substituted/substituted.
例えばN−メチルカルバモイル基、N−エチルカルバモ
イル基、N、N−ジメチルカルバモイル基、N−プロピ
ルカルバモイル基、N−イソプロピルカルバモイル基、
N−ブチルカルバモイル基、N−ペンチルカルバモイル
基又はN−ヘキシルカルバモイル基等の炭素数1ないし
6個の低級アルキル基l又は2個で置換されていてもよ
いカルバモイル基が挙げられる。For example, N-methylcarbamoyl group, N-ethylcarbamoyl group, N,N-dimethylcarbamoyl group, N-propylcarbamoyl group, N-isopropylcarbamoyl group,
Examples include carbamoyl groups optionally substituted with one or two lower alkyl groups having 1 to 6 carbon atoms, such as N-butylcarbamoyl, N-pentylcarbamoyl, or N-hexylcarbamoyl.
一般代[■コで表される本発明の目的化合物におけるR
’の好適な例としては1例えば水素原子、メチル基、エ
チル基、カルボキシメチル基、1−カルボキシ−1−メ
チルエチル基、l−カルボキシシクロプロビル基、1−
カルボキシジグロブチル基、1−カルボキシシクロペン
チル基、1−力ルボキシビニル基、2−カルボキシビニ
ル基、2−カルボキシエチニル基、フルオロメチル基、
2−フルオロエチル基。R in the target compound of the present invention represented by the general group [■
Preferred examples of ' include hydrogen atom, methyl group, ethyl group, carboxymethyl group, 1-carboxy-1-methylethyl group, l-carboxycycloprobyl group, 1-
Carboxydiglobutyl group, 1-carboxycyclopentyl group, 1-carboxyvinyl group, 2-carboxyvinyl group, 2-carboxyethynyl group, fluoromethyl group,
2-fluoroethyl group.
2.2−ジフルオロエチル基、クロルメチル基、2−ク
ロルエチル基、ブロモメチル基、2−ブロモエチル基、
ビニル基、エチニル基、3,4−ジヒドロキシベンジル
基、α−カルボキシ−3,4−ジヒドロキシベンジル基
又はベンジル基等が挙げられる。2.2-difluoroethyl group, chloromethyl group, 2-chloroethyl group, bromomethyl group, 2-bromoethyl group,
Examples include vinyl group, ethynyl group, 3,4-dihydroxybenzyl group, α-carboxy-3,4-dihydroxybenzyl group, and benzyl group.
一般代[Iコで表される本発明の目的化合物の3位の置
換基の好適な例としては、例えば、(1−メチルキノリ
ニウム−2−イル)チオメチル基、(1−メチルキノリ
ニウム−3−イル)チオメチル基、(1−メチルキノリ
ニウム−4−イル)チオメチル基、(1−メチルキノリ
ニウム−5−イル)チオメチル基、(1−メチルキノリ
ニウム−8−イル)チオメチル基、(1−カルボキシメ
チルキノリニウム−4−イル)チオメチル基、(1−カ
ルバモイルメチルキノリニウム−4−イル)チオメチル
基、[:1−(2−フルオロエチル)キノリニウム−4
−イルコチオメチル基、[1−(2−フルオロエチル)
キノリニウム−5−イルコチオメチル基、 [1−(2
−ジメチルアミノエチル)キノリニウム−4−イルコチ
オメチル基、(5−アミノ−1−メチルキノリニウム−
4−イル)チオメチル基、(8−クロル−1−メチルキ
ノリニウム−4−イル)チオメチル基、(6−ヒドロキ
シ−1−メチルキノリニウム−4−イル)チオメチル基
、 (6,7−シヒドロキシー1−メチルキノリニウム
−4−イル)チオメチル基又は[6,7−シヒドロキシ
ー1−(2−フルオロエチル)キノリニウム−4−イル
コチオメチル基等が挙げられる。Preferred examples of the substituent at the 3-position of the target compound of the present invention represented by the general group [I] include (1-methylquinolinium-2-yl)thiomethyl group, (1-methylquinolinium-2-yl), (1-methylquinolinium-2-yl), (1-methylquinolinium-2-yl), (1-methylquinolinium-3-yl)thiomethyl group, (1-methylquinolinium-4-yl)thiomethyl group, (1-methylquinolinium-5-yl)thiomethyl group, (1-methylquinolinium-8-yl) )thiomethyl group, (1-carboxymethylquinolinium-4-yl)thiomethyl group, (1-carbamoylmethylquinolinium-4-yl)thiomethyl group, [:1-(2-fluoroethyl)quinolinium-4
-ylkothiomethyl group, [1-(2-fluoroethyl)
Quinolinium-5-ylcothiomethyl group, [1-(2
-dimethylaminoethyl)quinolinium-4-ylcothiomethyl group, (5-amino-1-methylquinolinium-
4-yl)thiomethyl group, (8-chloro-1-methylquinolinium-4-yl)thiomethyl group, (6-hydroxy-1-methylquinolinium-4-yl)thiomethyl group, (6,7- Examples include a cyhydroxy-1-methylquinolinium-4-yl)thiomethyl group and a [6,7-cyhydroxy-1-(2-fluoroethyl)quinolinium-4-ylcothiomethyl group.
一般式[11で表される本発明化合物の無毒性塩として
は、例えばナトリウム、カリウム若しくはリチウム等の
アルカリ金属との塩、例えばカルシウム若しくはマグネ
シウム等のアルカリ土類金属との塩1例えばN、N’−
ジベンジルエチレンジアミン、エタノールアミン若しく
はトリエチルアミン等の有機アミンとの塩、例えば塩酸
、硝酸、硫酸若しくはリン酸等の無機酸との塩、例えば
クエン酸若しくは酒石酸等の有機酸との塩、例えばメタ
ンスルホン酸若しくはP−トルエンスルホン酸等の有機
スルホン酸との塩又は例えばアスパラギン酸、グルタミ
ン酸若しくはリジン等のアミノ酸との塩等が挙げられる
。Non-toxic salts of the compound of the present invention represented by the general formula [11] include salts with alkali metals such as sodium, potassium or lithium; salts with alkaline earth metals such as calcium or magnesium; '−
Salts with organic amines such as dibenzylethylenediamine, ethanolamine or triethylamine, salts with inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid or phosphoric acid, salts with organic acids such as citric acid or tartaric acid, such as methanesulfonic acid. Alternatively, salts with organic sulfonic acids such as P-toluenesulfonic acid, or salts with amino acids such as aspartic acid, glutamic acid, or lysine can be mentioned.
又、本発明化合物には7位側鎖のオキシイミノ基に由来
する幾何異性体[E体及び2体]が存在し、そのいずれ
も本発明は含有するが、好ましくは2体である。Furthermore, the compound of the present invention has geometric isomers [E-isomer and 2-isomer] derived from the oximino group in the 7-position side chain, both of which are included in the present invention, but 2-isomer is preferred.
次に本発明化合物の製造法について説明する。Next, a method for producing the compound of the present invention will be explained.
一般代
[式中、R“は水素原子、置換されていてもよい低級ア
ルキル基、置換されていてもよいシクロアルキル基、置
換されていてもよい低級アルケニル基、置換されていて
もよい低級アルキニル基、置換されていてもよいアリー
ル基又は置換されていてもよいアラルキル基を R1は
置換されていてもよい低級アルキル基、置換されていて
もよいシクロアルキル基、置換されていてもよい低級ア
ルケニル基又は置換されていてもよい低級アルキニル基
を、R1、R4及びR’は同−又は異なっていてもよく
、水素原子、ハロゲン原子、置換されていてもよい低級
アルキル基、水酸基、低級アルコキシ基、低級アルカノ
イルオキシ基、アミノ基、低級アルキルアミノ基、低級
アルカノイルアミノ基、カルボキシル基、低級アルコキ
シカルボニル基、置換されていてもよいカルバモイル基
、スルホ基、スルファモイル基、低級アルカノイル基又
はニトロ基をそれぞれ示す]で表される本発明の目的化
合物[11の製造は、
一般式
〔式中、R“°は水酸基の保護基又は前記のR“、若し
くはRoの官能基が保護された置換基を、Roは水素原
子又はアミノ基の保護基を、Roは水素原子又はカルボ
キシル基の保護基を、Xはハロゲン原子又はアセトキシ
基を示すコで表される化合物又はその塩を、
一般式[III]
[式中 Hllは水素原子又は前記のR3,若しくはR
1の官能基が保護された置換基をR”°、R“°及びR
o0はそれぞれ前記のR3、R4及びR’、若しくはR
3、R4及びRoの官能基が保護された置換基を示す]
で表される化合物と反応させ1次いで所望により。General group [wherein R'' is a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group, an optionally substituted lower alkynyl group R1 is an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group. group or optionally substituted lower alkynyl group, R1, R4 and R' may be the same or different, hydrogen atom, halogen atom, optionally substituted lower alkyl group, hydroxyl group, lower alkoxy group , lower alkanoyloxy group, amino group, lower alkylamino group, lower alkanoylamino group, carboxyl group, lower alkoxycarbonyl group, optionally substituted carbamoyl group, sulfo group, sulfamoyl group, lower alkanoyl group or nitro group, respectively. The production of the object compound [11] of the present invention represented by the general formula [wherein R"° is a hydroxyl-protecting group or the above-mentioned R" or a substituent in which the functional group of Ro is protected, Ro represents a hydrogen atom or a protecting group for an amino group, Ro represents a hydrogen atom or a protective group for a carboxyl group, and X represents a halogen atom or an acetoxy group. In the formula, Hll is a hydrogen atom or the above R3, or R
The substituents in which the functional group of 1 is protected are R"°, R"° and R
o0 is each of the above R3, R4 and R', or R
3, R4 and Ro functional groups represent protected substituents]
1. Then, as desired.
(+)キノリン環のN−アルキル化を行う工程(if)
保護基を除去する工程
(in)無毒性塩にする工程
以上の工程を1若しくはそれ以上行うことにより、行う
ことができる。(+) Step (if) of N-alkylating the quinoline ring
Step of removing the protecting group (in) Step of converting into a non-toxic salt This can be carried out by performing one or more of the above steps.
一般式[■]の化合物及び[tIl]の化合物との反応
は、一般代CI!1においてXがハロゲン原子の場合、
例えば塩化メチレン、クロロホルム、エーテル、酢酸エ
チル、酢酸ブチル、テトラヒドロフラン、アセトニトリ
ル、 N、N−ジメチルホルムアミド、ジメチルスルホ
キシド又はこれらの混合溶媒中で、脱酸剤の存在下、又
は非存在下に行うことができる。脱酸剤としては、例え
ば、炭酸ナトリウムS炭酸カリウム、炭酸カルシウム又
は炭酸マグネシウム等の金属塩又は例えばトリエチルア
ミン、ジイソプロピルエチルアミン、N−メチルモルホ
リン又はN、N−ジメチルアニリン等の有機アミンが挙
げられる1反応は一般式[0]の化合物1モルに対して
、一般代[mlの化合物を1〜2モル使用し1反応温度
及び反応時間は特に限定されないが、通常は0〜40℃
で0.5〜5時間である。The reaction between the compound of the general formula [■] and the compound of [tIl] is performed using the general formula CI! When X is a halogen atom in 1,
For example, it can be carried out in methylene chloride, chloroform, ether, ethyl acetate, butyl acetate, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, or a mixed solvent thereof, with or without a deoxidizing agent. can. Examples of deoxidizers include metal salts such as sodium carbonate, potassium carbonate, calcium carbonate or magnesium carbonate, or organic amines such as triethylamine, diisopropylethylamine, N-methylmorpholine or N,N-dimethylaniline. For 1 mol of the compound of general formula [0], 1 to 2 mol of the compound of general formula [ml] is used.The reaction temperature and reaction time are not particularly limited, but are usually 0 to 40°C.
It takes 0.5 to 5 hours.
又、一般代[II]においで、Xがアセトキシ基である
化合物と一般式[I11]の化合物との反応は、例えば
、水、リン酸緩衝液、アセトン、アセトニトリル、メタ
ノール、エタノール、テトラヒドロフラン、ジオキサン
、 N、N−ジメチルホルムアミド。In general formula [II], the reaction between the compound in which X is an acetoxy group and the compound of general formula [I11] can be carried out using, for example, water, phosphate buffer, acetone, acetonitrile, methanol, ethanol, tetrahydrofuran, dioxane. , N,N-dimethylformamide.
ジメチルスルホキシド又はこれらの混合溶媒中で行うこ
とができる1反応は中性付近で行うことが好ましく、反
応温度及び反応時間は特に限定されないが、通常は室温
〜90℃及び1〜15時間である。One reaction that can be carried out in dimethyl sulfoxide or a mixed solvent thereof is preferably carried out near neutrality, and the reaction temperature and reaction time are not particularly limited, but are usually room temperature to 90°C and 1 to 15 hours.
又本反応は5例えばヨウ化ナトリウム又はヨウ化カリウ
ム等のヨウ化物、例えばチオシアン酸ナトリウム又はチ
オシアン酸カリウム等のチオシアン酸塩又は例えばベン
ジルトリメチルアンモニウムプロミド等の第4級アンモ
ニウム塩等の存在下で行うことにより促進される。その
使用量は化合物[n11モルに対して1−20モルであ
る。This reaction can also be carried out in the presence of an iodide such as sodium iodide or potassium iodide, a thiocyanate such as sodium thiocyanate or potassium thiocyanate, or a quaternary ammonium salt such as benzyltrimethylammonium bromide. Facilitated by doing. The amount used is 1-20 mol per 11 mol of compound [n.
一般代[111と[III]の化合物との反応において
、一般代[I[1]のR1が水素原子の場合(即ちキノ
リンチオール化合物)1本反応後、アルキル化剤により
、キノリン環のトアルキル化反応を行う、アルキル化剤
としては1例えばヨウ化メチル、ヨウ化エチル、1−ブ
ロモ−2−フルオロエタン、ヨウ化酢酸ベンズヒドリル
エステル又はヨウ化酢酸アミド等の置換していてもよい
低級アルキルハライド。In the reaction between the compound of general group [111] and [III], when R1 of general group [I [1] is a hydrogen atom (i.e., a quinolinthiol compound), after one reaction, the quinoline ring is toalkylated with an alkylating agent. The alkylating agent used in the reaction is an optionally substituted lower alkyl halide such as methyl iodide, ethyl iodide, 1-bromo-2-fluoroethane, iodoacetic benzhydryl ester, or iodoacetic acid amide. .
例えばビニルクロライド又はヨウ化フリル等のアルケニ
ルハライド、例えばプロパルギルクロライド等のアルキ
ニルハライド、例えばヨウ化シクロプロピル、ヨウ化シ
クロブチル又はヨウ化シクロペンチル等のハロゲン化シ
クロアルキル、ジメチル硫酸、例えばフルオロスルホン
酸メチル、トリフルオロメタンスルホン酸メチル、トリ
フルオロメタンスルホン酸エチル等のアルキルスルホン
酸エステル等が挙げられる9本反応は、例えば水、アセ
トン、アセトニトリル、メタノール、エタノール、テト
ラヒドロフラン、 N、N−ジメチルホルムアミド、ジ
メチルスルホキシド、塩化メチレン。Alkenyl halides such as vinyl chloride or furyl iodide; alkynyl halides such as propargyl chloride; cycloalkyl halides such as cyclopropyl iodide, cyclobutyl iodide or cyclopentyl iodide; The nine reactions include alkyl sulfonate esters such as methyl lomethanesulfonate and ethyl trifluoromethanesulfonate. Examples of the nine reactions include water, acetone, acetonitrile, methanol, ethanol, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, and methylene chloride. .
クロロホルム又はこれらの混合溶媒中で、該アルキル化
剤を1〜5モル使用して行う二とができる。The reaction can be carried out using 1 to 5 moles of the alkylating agent in chloroform or a mixed solvent thereof.
反応温度及び反応時間は特に限定されないが、通常は一
10℃〜50℃で及び1〜24時間である。The reaction temperature and reaction time are not particularly limited, but are usually between -10°C and 50°C and between 1 and 24 hours.
以上の工程中、各種官能基は必要に応じ、保護されてい
てもよく、−保護基が存在する場合、最終的に保護基を
除去することにより、本発明化合物[+]を得ることが
できる。During the above steps, various functional groups may be protected as necessary, and when a - protecting group is present, the compound [+] of the present invention can be obtained by finally removing the protecting group. .
前記一般代におけるカルボキシル基、アミノ基及び水酸
基の保護基としては、β−ラクタム合成の分野で通常使
用されている保護基を適宜選択して使用することができ
る。As the protecting groups for the carboxyl group, amino group and hydroxyl group in the general group, protecting groups commonly used in the field of β-lactam synthesis can be appropriately selected and used.
保護基の導入及び除去方法は、その保護基の種類に応じ
て1例えばワイリイ(Wiley)社より1981年に
発行されたティ・ダブりニー・グリーン(T、 LGr
eene)著のプロテクティブ・グループス・イン・オ
ーガニック・シンセシス(Protective Gr
oups inOrganic 5ynthesis)
、プレナムプレス(PlenumPress)社より1
973年に発行されたジェイ・エフ・ダブリュー・マコ
ミイ−(J、F、賛、McOmte)著のプロテクティ
ブ・グループス・イン・オーガニック・ケミストリー(
Protective Groups in Orga
nic Chemis−try)等に記載されている方
法を適宜選択して行うことができる。カルボキシル基の
保護基としては、例えばt−ブチル基、 2,2.24
リクロロエチル基、アセトキシメチル基、プロピオニル
オキシメチル基、ピバロイルオキシメチル基、l−アセ
トキシエチル基、l−プロピオニルオキシエチル基、1
−(エトキシカルボニルオキシ)エチル基、フタリジル
基、ベンジル基、4−メトキシベンジル基、3,4−ジ
メトキシベンジル基、4−ニトロベンジル基、ベンズヒ
ドリル基、ビス(4−メトキシフェニル)メチル基、(
5−メチル−2−オキソ−1,3−ジオキソ−ルー4−
イル)メチル基、トリメチルシーノル基、tert−ブ
チルジメチルシリル基等が挙げられ、特にベンズヒドリ
ル基、 tert−ブチル基又はシリル基等が好ましい
。Methods for introducing and removing protecting groups vary depending on the type of protecting group.
Protective Groups in Organic Synthesis (Protective Groups in Organic Synthesis) by
oups inOrganic 5 synthesis)
, from Plenum Press 1
Protective Groups in Organic Chemistry, written by J.F. McOmte, published in 1973.
Protective Groups in Orga
This can be carried out by appropriately selecting a method described in NIC Chemis-try) and the like. As a protecting group for carboxyl group, for example, t-butyl group, 2,2.24
Lichloroethyl group, acetoxymethyl group, propionyloxymethyl group, pivaloyloxymethyl group, l-acetoxyethyl group, l-propionyloxyethyl group, 1
-(Ethoxycarbonyloxy)ethyl group, phthalidyl group, benzyl group, 4-methoxybenzyl group, 3,4-dimethoxybenzyl group, 4-nitrobenzyl group, benzhydryl group, bis(4-methoxyphenyl)methyl group, (
5-Methyl-2-oxo-1,3-dioxo-4-
yl)methyl group, trimethylshinol group, tert-butyldimethylsilyl group, etc., and particularly preferred are benzhydryl group, tert-butyl group, and silyl group.
アミノ基の保護基としては、例えばトリチル基、ホルミ
ル基、クロロアセチル基、トリフルオロアセチル基、t
ert−ブトキシカルボニル基、トリメチルシリル基又
はtert−ブチルジメチルシリル基等が挙げられる。Examples of protecting groups for amino groups include trityl group, formyl group, chloroacetyl group, trifluoroacetyl group, t
Examples include ert-butoxycarbonyl group, trimethylsilyl group, and tert-butyldimethylsilyl group.
水酸基の保護基としては、例えば2−メトキシエトキシ
メチル基、メトキシメチル基、メチルチオメチル基、テ
トラヒドロピラニル基、フェナシル基、イソプロピル基
、tert−ブチル基、ベンジル基、4−ニトロベンジ
ル基、アセチル基、2,2.2−トリクロロエトキシカ
ルボニル基、ベンジルオキシカルボニル基、トリメチル
シリル基、 tert−ブチルジメチルシリル基又は例
えば保護基が互いに結合して形成する、メトキシエチリ
デン、メトキシエチリデン等のオルトエステル、ベンジ
リデンアセタール、メチレンアセタール、エチレンアセ
タール等の環状アセタール、イソプロピリデンケタール
等の環状ケタール及び環状の炭酸エステル等が挙げられ
る。Examples of protecting groups for hydroxyl groups include 2-methoxyethoxymethyl group, methoxymethyl group, methylthiomethyl group, tetrahydropyranyl group, phenacyl group, isopropyl group, tert-butyl group, benzyl group, 4-nitrobenzyl group, and acetyl group. , 2,2.2-trichloroethoxycarbonyl group, benzyloxycarbonyl group, trimethylsilyl group, tert-butyldimethylsilyl group or, for example, orthoesters such as methoxyethylidene, methoxyethylidene, etc., formed by combining protective groups with each other, benzylidene acetal , cyclic acetals such as methylene acetal and ethylene acetal, cyclic ketals such as isopropylidene ketal, and cyclic carbonate esters.
保護基の除去方法を具体的に説明すると、トリチル基、
ホルミル基、tert−ブトキシカルボニル基、ベンズ
ヒドリル基、tert−ブチル基又は2−メトキシエト
キシメチル基等の保護基の除去は、例えば塩酸、ギ酸、
トリフルオロ酢酸、ベンゼンスルホン酸又はP−トルエ
ンスルホン酸等の無機酸又は有機酸等で行うことができ
、特にトリフルオロ酢酸が好ましい。To explain specifically how to remove the protecting group, trityl group,
Removal of protecting groups such as formyl group, tert-butoxycarbonyl group, benzhydryl group, tert-butyl group or 2-methoxyethoxymethyl group can be carried out using, for example, hydrochloric acid, formic acid,
This can be carried out using an inorganic or organic acid such as trifluoroacetic acid, benzenesulfonic acid or P-toluenesulfonic acid, with trifluoroacetic acid being particularly preferred.
尚、酸としてトリフルオロ酢酸を使用する場合には、ア
ニソール、チオアニソール又はフェノールを添加するこ
とによって反応は促進され、副反応も抑制される。In addition, when trifluoroacetic acid is used as the acid, the reaction is promoted and side reactions are also suppressed by adding anisole, thioanisole or phenol.
又1反応は例えば水、塩化メチレン、クロロホルム、塩
化エチレン、ベンゼン又はこれらの混合溶媒等の反応に
関与しない溶媒中で行うことができる0反応温度及び反
応時間は化合物[II]及び本発明化合物[11の化学
的性質、保護基の種類に応じて適宜選択し、特に水冷な
゛いしは加温程度の条件で行うのが好ましい。In addition, the reaction can be carried out in a solvent that does not participate in the reaction, such as water, methylene chloride, chloroform, ethylene chloride, benzene, or a mixed solvent thereof.The reaction temperature and reaction time are suitable for compound [II] and the present compound [ It is suitably selected depending on the chemical properties of No. 11 and the type of protecting group, and it is particularly preferable to carry out the reaction under conditions of water cooling or heating.
本発明化合物の合成中間体である一般式[11]で表さ
れる化合物は、一般代
[式中、R″及びXは前記の意味を有する]で表される
化合物を、一般代
[式中、R″及びR10は前記の意味を有する]で表さ
れる化合物又はそのカルボキシル基の反応性誘導体に反
応させることにより製造することができる。The compound represented by the general formula [11], which is a synthetic intermediate for the compound of the present invention, is a compound represented by the general formula [in the formula, R'' and X have the above-mentioned meanings]. , R'' and R10 have the above-mentioned meanings] or a reactive derivative of its carboxyl group.
一般代[IV]で表される化合物を、一般代[Vlで表
される化合物又はそのカルボキシル基の反応性誘導体に
反応させて、一般代[1]で表される化合物を製造する
工程は、例えば水、アセトン、ジオキサン、エーテル、
テトラヒドロフラン、エチルメチルケトン、クロロホル
ム、塩化メチレン、ジクロルエタン、酢酸エチル、ギ酸
エチル、N、N−ジメチルホルムアミド、ジメチルスル
ホキシド又はそれらの混合溶媒等の反応に悪影響を及ぼ
さない溶媒中、反応温度として冷却下ないし室温下及び
反応時間として1時間ないし10時間という条件下で行
うことができる。一般代[Vlで表される化合物のカル
ボキシル基の反応性誘導体としては、例えばN、N’−
ジシクロへキシルカルボジイミド等の脱水剤及び例えば
N−ヒドロキシコハク酸イミド又は1−ヒドロキシベン
ゾトリアゾール等により形成される活性エステル;例え
ば塩化チオニル、五塩化リン又はオキザリルクロライド
等のハロゲン化剤により形成される酸ハロゲン化物;例
えばトリエチルアミン又はN−メチルモルホリン等の脱
酸剤及び例えばメチルグロルホルメート又はイソブチル
クロルホルメート等のクロル炭酸エステルにより形成さ
れる混合酸無水物等が挙げられる。また用いられる該カ
ルボン酸の反応性誘導体の種類によっては、塩基の存在
下に反応させるのが、反応を円滑に進行させる上で好ま
しい場合もある6かかる塩基としては、例えば炭酸水素
カリウム、炭酸ナトリウム若しくは炭酸カリウム等の無
機塩基又は例えばトリメチルアミン、トリエチルアミン
、N、N−ジメチルアニリン若しくはピリジン等の有機
塩基が挙げられる6加えて、一般代[Vlで表される化
合物を遊離カルボン酸の状態で使用するときは、N、N
’−ジシクロへキシルカルボジイミド又はN。The step of producing a compound represented by general group [1] by reacting a compound represented by general group [IV] with a compound represented by general group [Vl or a reactive derivative of its carboxyl group] is as follows: For example, water, acetone, dioxane, ether,
In a solvent that does not adversely affect the reaction, such as tetrahydrofuran, ethyl methyl ketone, chloroform, methylene chloride, dichloroethane, ethyl acetate, ethyl formate, N,N-dimethylformamide, dimethyl sulfoxide, or a mixed solvent thereof, under cooling or at a reaction temperature of The reaction can be carried out at room temperature and for a reaction time of 1 to 10 hours. Examples of reactive derivatives of the carboxyl group of the compound represented by the general group [Vl include N, N'-
Active esters formed with dehydrating agents such as dicyclohexylcarbodiimide and, for example, N-hydroxysuccinimide or 1-hydroxybenzotriazole; formed with halogenating agents, such as thionyl chloride, phosphorus pentachloride, or oxalyl chloride. Acid halides; for example, mixed acid anhydrides formed by deoxidizing agents such as triethylamine or N-methylmorpholine and chlorocarbonate esters such as methyl chloroformate or isobutyl chloroformate; Furthermore, depending on the type of the reactive derivative of the carboxylic acid used, it may be preferable to carry out the reaction in the presence of a base to allow the reaction to proceed smoothly.6 Examples of such bases include potassium hydrogen carbonate, sodium carbonate, etc. or an inorganic base such as potassium carbonate or an organic base such as trimethylamine, triethylamine, N,N-dimethylaniline or pyridine. Time is N, N
'-dicyclohexylcarbodiimide or N.
N′−ジエチルカルボジイミド等の縮合剤を使用するの
が好ましい、なお、一般代[IV’lで表される化合物
は、ジャーナル・オブ・アンティバイオティクス(J
、Antibiotics )、第38巻、1738頁
(1985年)に記載の方法に準じて製造することがで
き、また−般代[Vlで表される化合物は、例えばケミ
カル・アンド・ファーマシュウティカル・ブレティン(
Chew、 Pharm、Bull、)、第25巻、3
115頁(1977年)及び日本化学会雑誌、785頁
(1981年)等に記載の方法に準じて製造できる。It is preferable to use a condensing agent such as N'-diethylcarbodiimide. Note that compounds represented by the general group [IV'l] are described in the Journal of Antibiotics (J
Antibiotics), Vol. 38, p. 1738 (1985). (
Chew, Pharm, Bull, ), Volume 25, 3
It can be produced according to the method described in p. 115 (1977) and Journal of the Chemical Society of Japan, p. 785 (1981).
一般式[I11]の化合物は、キノリルチオール又はキ
ノリニウムチオールを示すが、チオール基の置換位置に
よっては(例えば2若しくは4位など)次のような互変
異性系を形成する。The compound of general formula [I11] represents quinolylthiol or quinoliniumthiol, and forms the following tautomeric system depending on the substitution position of the thiol group (for example, the 2- or 4-position).
一般式[III]で表される化合物は、それ自体公知で
あるか、又は公知の一般的反応により合成することがで
きる0例えば対応するキノリン誘導体の塩化スルホニル
基の還元、水酸基と三硫化リンの反応、塩素原子と水硫
化ナトリウムの反応1インチウロニウム基若しくはジチ
オ炭酸エステル等の加水分解などによって容易に得るこ
とができる。The compound represented by the general formula [III] is known per se or can be synthesized by a known general reaction. It can be easily obtained by reaction, reaction between chlorine atom and sodium hydrogen sulfide, hydrolysis of 1 inch uronium group or dithiocarbonate, etc.
本発明の化合物は優れた抗菌活性を示し、医薬として有
用な新規化合物であり、細菌感染症、例えば呼吸器感染
症、尿路感染症、化膿性疾患又は外科感染症等の治療及
び予防に用いることができる。また、その投与方法とし
ては、静脈内注射。The compounds of the present invention exhibit excellent antibacterial activity and are novel compounds useful as pharmaceuticals, and are used for the treatment and prevention of bacterial infections, such as respiratory infections, urinary tract infections, purulent diseases, or surgical infections. be able to. The method of administration is intravenous injection.
筋肉内注射若しくは坐剤等による非経口投与又は錠剤、
散剤、カプセル剤若しくはシロップ剤等による経口投与
が適用される。なお、これらの剤形を製造するに際して
は、この分野における常法によることができ、例えば助
剤、湿潤剤、乳化剤、結合剤又は賦形剤等の通常使用さ
れる添加剤が含まれていてもよい、その投与量は、年齢
、性別。Parenteral administration via intramuscular injection or suppositories, or tablets;
Oral administration using powders, capsules, syrups, etc. is applicable. Note that these dosage forms can be produced by conventional methods in this field, and may contain commonly used additives such as auxiliaries, wetting agents, emulsifiers, binders, or excipients. The dosage may also depend on age and gender.
体重、感受性差、投与方法、投与の時間及び間隔、病状
の程度、体調、医薬製剤の性質、調剤の種類又は有効成
分の種類等を考慮して、決定されるが、通常は1日当り
1〜100mg/kgの範囲であり、1日当り5〜30
ntg/−で2〜4回に分けて投与することが好ましい
。It is determined by taking into account body weight, sensitivity difference, administration method, time and interval of administration, degree of medical condition, physical condition, properties of pharmaceutical preparation, type of preparation, type of active ingredient, etc., but usually 1 to 100 mg per day. 100mg/kg, 5-30 mg/day
It is preferable to administer ntg/- in 2 to 4 divided doses.
本発明化合物の有用性を具体的に示すために、種々の細
菌に対する試験管内抗菌活性を下記の寒天平板希釈法に
より測定した。すなわち、ミューラー・ヒントン・ブロ
ス中で一夜培養した各試験菌株の一白金耳(接種菌量:
lO’CFU/illりをミューラー・ヒントン・アガ
ーに接種した。この培地には、供試薬剤が所定の濃度含
まれており、37℃で16時間培養した後、最小発育阻
止濃度(MIC,g/m(+)を測定した。その結果を
表に示す。In order to specifically demonstrate the usefulness of the compounds of the present invention, in vitro antibacterial activity against various bacteria was measured by the agar plate dilution method described below. That is, one loopful of each test strain cultured overnight in Mueller-Hinton broth (inoculum amount:
Mueller-Hinton agar was inoculated with 10'CFU/ill. This medium contained the test drug at a predetermined concentration, and after culturing at 37° C. for 16 hours, the minimum inhibitory concentration (MIC, g/m(+)) was measured. The results are shown in the table.
表から明らかな如く、本発明に係わる化合物は多種の試
験菌に対し1幅広く抗菌活性を示すことがわかる。As is clear from the table, it can be seen that the compounds according to the present invention exhibit a wide range of antibacterial activity against a wide variety of test bacteria.
(以下余白)
341匹
以下本発明を実施例及び参考例により、さらに詳細に説
明する。(The following is a blank space) 341 animals The present invention will be explained in more detail with reference to Examples and Reference Examples.
実施例1
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−メトキシイミノアセトアミド]−3−[(1
−メチルキノリニウム−4−イル)チオメチル]−3−
セフェムー4−カルボキシレート
7β−[2−(2−トリチルアミノチアゾール−4−イ
ル)−(Z)−2−メトキシイミノアセトアミド]−3
−ヨードメチル−3−セフェム−4−カルボン酸ベンズ
ヒドリルエステル466mg(0,5ma+ol)をN
、N−ジメチルホルムアミド6meに溶解し、室温下、
N−メチルキノリン−4−チオン87.5mg(0,5
mmol)を加え、1時間攪拌する。Example 1 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-methoxyiminoacetamide]-3-[(1
-methylquinolinium-4-yl)thiomethyl]-3-
Cephemu 4-carboxylate 7β-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetamide]-3
-Iodomethyl-3-cephem-4-carboxylic acid benzhydryl ester 466 mg (0.5 ma + ol) was added to N
, dissolved in N-dimethylformamide 6me, at room temperature,
N-methylquinoline-4-thione 87.5 mg (0,5
mmol) and stirred for 1 hour.
溶媒を留去した後、残渣をイソプロピルエーテルでトリ
チュレートして、7β−[2−(2−トリチルアミノチ
アゾール−4−イル)−(Z)−2−メトキシイミノア
セトアミド]−3−[(i−メチルキノリニウム−4−
イル)チオメチル]−3−セフェムー4−カルボン酸ベ
ンズヒドリルエステルアイオダイド363mg(収率6
5.4%)を得る。このうち352i+g(0,317
mff1ol )を塩化メチレン1.8d及びアニソー
ル0.38meに溶解し、水冷下トリフルオロ酢酸2.
8−を加え、同温度で1時間攪拌する。溶媒を留去した
後、残渣にイソプロピルエーテルを加え、標記化合物の
トリフルオロ酢酸塩を粉末として得る。これを水に溶解
し、炭酸水素ナトリウム水溶液でpH6,5に合わせ、
逆相カラムクロマトグラフィー(ケムコLC−5ORB
、 5P−B−ODS。After evaporation of the solvent, the residue was triturated with isopropyl ether to give 7β-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetamide]-3-[(i- Methylquinolinium-4-
yl)thiomethyl]-3-cephemu 4-carboxylic acid benzhydryl ester iodide 363 mg (yield 6
5.4%). Of these, 352i+g (0,317
mff1ol) was dissolved in 1.8 d of methylene chloride and 0.38 me of anisole, and 2.0 d of trifluoroacetic acid was dissolved under water cooling.
Add 8- and stir at the same temperature for 1 hour. After distilling off the solvent, isopropyl ether is added to the residue to obtain the trifluoroacetate of the title compound as a powder. Dissolve this in water, adjust the pH to 6.5 with an aqueous sodium hydrogen carbonate solution,
Reversed phase column chromatography (Chemco LC-5ORB
, 5P-B-ODS.
40〜50%メタノール水溶液で一溶出)で精製し、凍
結乾燥して、標記化合物51.2mg(収率28.3%
)を得る。The title compound was purified by eluting with a 40-50% aqueous methanol solution and lyophilized to give 51.2 mg of the title compound (yield 28.3%).
).
mp:155〜160℃(分解)
I R(KBr)−:3400,1765,1670,
1610,1560,153ON M R(DMSO−
d、 )δ:3.84(3H,s)、4.46(3H,
s)。mp: 155-160°C (decomposition) IR (KBr)-: 3400, 1765, 1670,
1610, 1560, 153 ON MR (DMSO-
d, ) δ: 3.84 (3H, s), 4.46 (3H,
s).
4.70(2H,bs)、5.03(IH,d、J=5
Hz)、5.58(LH,dd。4.70 (2H, bs), 5.03 (IH, d, J=5
Hz), 5.58 (LH, dd.
J=5&7Hz) 、6.74(LH,s)、7.25
(2)1.bs)、7.2〜9.3(6H,m)、9.
54(LH,d、J=7Hz)実施例1と同様な方法で
、以下の実施例2〜4の化合物を合成した。J=5&7Hz), 6.74(LH,s), 7.25
(2)1. bs), 7.2-9.3 (6H, m), 9.
54 (LH, d, J=7Hz) In the same manner as in Example 1, the following compounds of Examples 2 to 4 were synthesized.
実施例2
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−メトキシイミノアゼドアミドコ−3−([1
−(2−フルオロエチル)キノリニウム−4−イルコチ
オメチル)−3−セフェム−4−カルボキシレート
m p : 145〜150℃(分解)I R(KBr
)a(:3400,1770,1670,1600,1
530,1380゜1350.1160,1035.7
6ON M R(DMSO−d、 )δ:3.42,3
.64(2B、ABq、J=17Hz)。Example 2 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-methoxyiminoazedoamide co-3-([1
-(2-fluoroethyl)quinolinium-4-ylcothiomethyl)-3-cephem-4-carboxylate m p: 145-150°C (decomposition) I R (KBr
)a(:3400,1770,1670,1600,1
530,1380°1350.1160,1035.7
6ON MR(DMSO-d, )δ:3.42,3
.. 64 (2B, ABq, J=17Hz).
3.82(3H,s)、4.73(2H,bs)、4.
98(28,d、J”46Hz)。3.82 (3H, s), 4.73 (2H, bs), 4.
98 (28, d, J”46Hz).
5.04(LH,d、Jl15Hz) 、5.34(2
H,d、J=27Hz)、5.59(IFI、dd、J
=5&8Hz) 、6.75(111,s)、7.24
(2H,bs)。5.04 (LH, d, Jl15Hz), 5.34 (2
H, d, J = 27 Hz), 5.59 (IFI, dd, J
=5&8Hz), 6.75 (111,s), 7.24
(2H, bs).
7.97(IH,d、J=7)1z)、8.52(2t
l、bs)、8.79(In、d。7.97 (IH, d, J = 7) 1z), 8.52 (2t
l, bs), 8.79 (In, d.
J=8Hz)、8.84(IH,d、J=8Hz)、9
.19(IH,d、J=7Hz)。J=8Hz), 8.84 (IH, d, J=8Hz), 9
.. 19 (IH, d, J=7Hz).
9.55(II、d、J=8I(Z)
実施例3
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−メトキシイミノアセトアミド]−3−(1−
カルボキシメチルキノリニウム−4−イル)チオメチル
−3−セフェム−4−カルボキシレートナトリウムm
p : 165−175℃(分解)I R(KBr)a
i :3400,1770,1620,1530,13
80,1210゜1180.1010
4ON (DMSO−d、+D、0)δ:3.45,
3.64(2H,ABq。9.55(II, d, J=8I(Z) Example 3 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-methoxyiminoacetamide]-3-(1-
Carboxymethylquinolinium-4-yl)thiomethyl-3-cephem-4-carboxylate sodium m
p: 165-175℃ (decomposition) I R (KBr)a
i: 3400, 1770, 1620, 1530, 13
80,1210°1180.1010 4ON (DMSO-d, +D, 0) δ: 3.45,
3.64 (2H, ABq.
JJ8Hz)、3.83(3H,s)、4.67(2B
、bs)、5.04(LH,d。JJ8Hz), 3.83 (3H, s), 4.67 (2B
, bs), 5.04 (LH, d.
J”5Hz)、5.22(2H,bs)、5.61(L
H,d、J”5Hz)、6.71(IH,s)、8.0
(lfl、d、J=7Hz)、8.14(2H,bs)
、8.37(IH,d、J=8Hz)、8.47(1B
、d、J”8Hz) 、8.96(IH,d。J"5Hz), 5.22 (2H, bs), 5.61 (L
H, d, J”5Hz), 6.71 (IH, s), 8.0
(lfl, d, J=7Hz), 8.14 (2H, bs)
, 8.37 (IH, d, J=8Hz), 8.47 (1B
, d, J”8Hz) , 8.96 (IH, d.
J=7Hz)
実施例4
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−メトキシイミノアゼドアミド]−3−(6,
7−シヒドロキシー1−メチルキノリニウム−4−イル
)チオメチル−3−セフェム−4−カルボキシレート
m p : 170−180℃(分解)r R(KBr
)ail :3400,1770,1670,1620
,1555,1505゜1290.1170,1100
.104ON M R(DIIISO−d、+D□O)
δ:3.36,3.61(28,ABq。J=7Hz) Example 4 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-methoxyiminoazedoamide]-3-(6,
7-hydroxy-1-methylquinolinium-4-yl)thiomethyl-3-cephem-4-carboxylate mp: 170-180°C (decomposition) r R (KBr
) ail: 3400, 1770, 1670, 1620
,1555,1505゜1290.1170,1100
.. 104ON MR (DIIISO-d, +D□O)
δ: 3.36, 3.61 (28, ABq.
J=18Hz)、3.82(3H,s)、3.94(3
H,s)、4.98(11,d。J = 18Hz), 3.82 (3H, s), 3.94 (3
H,s), 4.98 (11,d.
J=5Hz)、5.62(IH,d、J=5Hz)、6
.55(IH,s)、6.75(IH,s)、7.14
(18,d、J=7H1)、7.95(IH,S)、8
.08(IH,d、J=7H2)
実施例5
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−(1−カルボキシ−1−メチルエトキシイミ
ノ)アセトアミド]−3−(1−メチルキノリニウム−
4−イル)チオメチル−3−セフェム−4−カルボキシ
レート ナトリウム
7β−C2−<2−トリチルアミノチアゾール−4−イ
ル)−(Z)−2−(1−ジフェニルメトキシカルボニ
ル−1−メチルエトキシイミノ)アセトアミトコ−3−
ヨードメチル−3−セフェム−4−カルボン酸ベンズヒ
ドリルエステル585mg(0,5m+*ol)をN、
N−ジメチルホルムアミド6dに溶解し、室温下、N−
メチルキノリン−4−チオン87.5mg(0,5mm
ol )を加え、1時間攪拌する。溶媒を留去した後、
残渣をイソプロピルエーテルでトリチュレートして、7
β−[2−(2−トリチルアミノチアゾール−4−イル
)−(Z)−2−(1−ジフェニルメトキシカルボニル
−1−メチルエトキシイミノ)アセトアミド]−3−[
(1−メチルキノリニウム−4−イル)チオメチルツー
3−セフェム−4−カルボン酸ベンズヒドリルエステル
アイオダイド468II1g(収率69.9%)を得る
。J=5Hz), 5.62 (IH, d, J=5Hz), 6
.. 55 (IH, s), 6.75 (IH, s), 7.14
(18, d, J=7H1), 7.95 (IH, S), 8
.. 08 (IH, d, J = 7H2) Example 5 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-(1-carboxy-1-methylethoxyimino)acetamide]-3-(1-methylquinolinium-
4-yl)thiomethyl-3-cephem-4-carboxylate Sodium 7β-C2-<2-tritylaminothiazol-4-yl)-(Z)-2-(1-diphenylmethoxycarbonyl-1-methylethoxyimino) Acetamitoco-3-
585 mg (0.5 m++ ol) of iodomethyl-3-cephem-4-carboxylic acid benzhydryl ester with N,
Dissolved in N-dimethylformamide 6d and added N- at room temperature.
Methylquinoline-4-thione 87.5 mg (0.5 mm
ol) and stir for 1 hour. After distilling off the solvent,
Trituration of the residue with isopropyl ether gives 7
β-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-(1-diphenylmethoxycarbonyl-1-methylethoxyimino)acetamide]-3-[
1 g (yield: 69.9%) of (1-methylquinolinium-4-yl)thiomethyl2-3-cephem-4-carboxylic acid benzhydryl ester iodide 468II is obtained.
このうち460mg(0,343mmol)を塩化メチ
レン1 、9 mQ及びアニソール0.41m9に溶解
し、水冷下トリフルオロ酢酸3威を加え、同温度で1時
間攪拌する。溶媒を留去した後、残渣にイソプロピルエ
ーテルを加え、標記化合物のトリフルオロ酢酸塩を粉末
として得る。これを水に溶解し炭酸水素ナトリウム水溶
液でpH6,5に合わせ、逆相カラムクロマトグラフィ
ー(ケムコLC−3ORB 、 5P−B−ODS 、
40〜50&メタノール水溶液で溶出)で精製し、凍
結乾燥して、標記化合物128mg(収率28.3%)
を得る。Of this, 460 mg (0,343 mmol) was dissolved in 1,9 mQ of methylene chloride and 0.41 m9 of anisole, and 3 parts of trifluoroacetic acid was added under water cooling, followed by stirring at the same temperature for 1 hour. After distilling off the solvent, isopropyl ether is added to the residue to obtain the trifluoroacetate of the title compound as a powder. This was dissolved in water, adjusted to pH 6.5 with an aqueous sodium bicarbonate solution, and subjected to reverse phase column chromatography (Chemco LC-3ORB, 5P-B-ODS,
40-50 & elution with an aqueous methanol solution) and lyophilized to give 128 mg (yield 28.3%) of the title compound.
get.
m p + 150−160℃(分解)I R(KBr
)aW :3400,1765,1660,1600.
153ON M R(DMSO−d、 )δ:1.37
(311,S)、1.42(3H,S)。m p + 150-160℃ (decomposition) I R (KBr
) aW: 3400, 1765, 1660, 1600.
153ON MR(DMSO-d, )δ: 1.37
(311,S), 1.42 (3H,S).
4.49(3H,s)、4.50,4.87(2H,A
Bq、J=13Hz)、5.04(IH,d、J=5H
z)、5.67(IH,dd、J=5&9)1z)、6
.71(LH,s)、7.20(IH,bs)、7.3
−7.4(6H,o+)実施例5と同様の方法で、以下
の実施例6〜8の化合物を合成した。4.49 (3H, s), 4.50, 4.87 (2H, A
Bq, J=13Hz), 5.04(IH, d, J=5H
z), 5.67 (IH, dd, J=5 & 9) 1z), 6
.. 71 (LH, s), 7.20 (IH, bs), 7.3
-7.4 (6H, o+) In the same manner as in Example 5, the following compounds of Examples 6 to 8 were synthesized.
実施例6
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−(1−カルボキシ−1−メチルエトキシイミ
ノ)アセトアミド]〜3−f(:1−(2−フルオロエ
チル)キノリニウム−4−イルコチオメチル)−3−セ
フェム−4−カルボキシレートナトリウム
mp:150〜160℃(分解)
I R(KBr)a(:3400,1770,1600
,1530,1400,1360゜1200.116O
N M R(DMSO−d、+D、O)δ:1.42(
61(、S)、3.45゜3.66(2B、ABq、J
’17Hz)、4.66(2H,bs)、5.0(2H
,d。Example 6 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-(1-carboxy-1-methylethoxyimino)acetamide]~3-f(:1-(2-fluoroethyl)quinolinium-4-ylcothiomethyl)-3-cephem-4-carboxylate sodium mp: 150-160℃ (decomposition) I R (KBr) a (: 3400, 1770, 1600
, 1530, 1400, 1360° 1200.116O NMR (DMSO-d, +D, O) δ: 1.42 (
61 (, S), 3.45° 3.66 (2B, ABq, J
'17Hz), 4.66 (2H, bs), 5.0 (2H
,d.
J’46Hz)、5.08(IFI、d、J=5Hz)
、5.28(2H,d、J=26Hz )、5.72(
IH,d 、J=5Hz)、6.8(LH、s )、8
.05(Iff 、d 。J'46Hz), 5.08 (IFI, d, J=5Hz)
, 5.28 (2H, d, J=26Hz), 5.72 (
IH, d, J=5Hz), 6.8 (LH, s), 8
.. 05(Iff, d.
J=7)1z)、8.28(2H,d、J=7Hz)、
8.46(IH,d、J=8Hz)。J=7)1z), 8.28(2H,d, J=7Hz),
8.46 (IH, d, J=8Hz).
8.56(IH,d、J=8Hz)、9.05(IH,
d、J=7Hz)実施例7
7β−[:2−(2−アミノチアゾール−4−イル)−
(Z)−2−(l−カルボキシ−1−メチルエトキシイ
ミノ)アセトアミド]−3−(1−カルボキシメチルキ
ノリニウム−4−イル)チオメチル−3−セフェム−4
−カルボキシレート2−ナトリウム
m p : 145−155℃(分解)I R(KBr
)aW :3400,1770,1600,1530
,1380,1200゜16O
N M R(DMSO−d、)δ:1.40(3H,s
)、1.42(3H,s)。8.56 (IH, d, J=8Hz), 9.05 (IH,
d, J=7Hz) Example 7 7β-[:2-(2-aminothiazol-4-yl)-
(Z)-2-(l-carboxy-1-methylethoxyimino)acetamide]-3-(1-carboxymethylquinolinium-4-yl)thiomethyl-3-cephem-4
-Sodium carboxylate 2-sodium m p: 145-155°C (decomposition) I R (KBr
) aW: 3400, 1770, 1600, 1530
, 1380, 1200° 16O NMR (DMSO-d,) δ: 1.40 (3H, s
), 1.42 (3H, s).
3.42,3.63(2H,ABq、J−18!Tz)
、4.57,4.77(2fl。3.42, 3.63 (2H, ABq, J-18!Tz)
, 4.57, 4.77 (2fl.
ABq、J=14Hz)、5.04(IH,d、J=5
Hz)、5.23(2B、s)。ABq, J=14Hz), 5.04(IH, d, J=5
Hz), 5.23 (2B, s).
5.69(LH,d、J=5Hz)、6.76(1!(
、s)、7.99(LH,d、J=8Hz)、8.14
(2■、bs)、8.23(IH,d、J=7)1z)
、8.48(IH,d、J=8Hz)、8.98(II
、d、J=71fz)実施例8
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−(l−カルボキシ−1−メチルエトキシイミ
ノ)アセトアミトコ−3−(6,7−シヒドロキシー1
−メチルキノリニウム−4−イル)チオメチル−3−セ
フェム−4−カルボキシレートナトリウム
m り : 175〜185℃(分解)I R(KBr
)Cil:3400,1780,1610,1520,
1370,1150゜1100.98O
NMR(DMSO−d、+D、O)δ:1.40(3H
,s)、1.42(31(。5.69 (LH, d, J = 5Hz), 6.76 (1! (
, s), 7.99 (LH, d, J=8Hz), 8.14
(2■, bs), 8.23 (IH, d, J=7) 1z)
, 8.48 (IH, d, J=8Hz), 8.98 (II
, d, J=71fz) Example 8 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-(l-carboxy-1-methylethoxyimino)acetamitoco-3-(6,7-cyhydroxy-1
Sodium -methylquinolinium-4-yl)thiomethyl-3-cephem-4-carboxylate: 175-185°C (decomposition) IR (KBr
) Cil: 3400, 1780, 1610, 1520,
1370, 1150° 1100.98O NMR (DMSO-d, +D, O) δ: 1.40 (3H
,s), 1.42(31(.
s)、3.42.3.67(2H,ABq、J=18H
z)、4.0(3H,s)。s), 3.42.3.67 (2H, ABq, J=18H
z), 4.0 (3H, s).
5.04(IH,d、、I’5Hz)、5.68(IH
,d、に5tlz)、6.61(IH,s)、6.81
(IH,s)、7.20(IH,d、J=7Hz)、8
.01(LH,s)、8.14(11(、d、に7Hz
)実施例9
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−メトキシイミノアセトアミド]−3−(1−
メチルキノリニウム−5−イル)チオメチル−3−セフ
ェム−4−カルボキシレート
5−ベンゾイルチオキノリン100II+g(0,37
7mmol)を6N塩酸2已に溶かし、1時間加熱還流
する0反応液を放冷し、エーテルで洗った後、 6N水
酸化ナトリウムでpH3,0に合わせ、塩化メチレンで
抽出する。5.04 (IH, d, , I'5Hz), 5.68 (IH
, d, 5tlz), 6.61 (IH, s), 6.81
(IH, s), 7.20 (IH, d, J=7Hz), 8
.. 01(LH,s), 8.14(11(,d, 7Hz
) Example 9 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-methoxyiminoacetamide]-3-(1-
Methylquinolinium-5-yl)thiomethyl-3-cephem-4-carboxylate 5-benzoylthioquinoline 100II+g (0,37
Dissolve 7 mmol) in 2 volumes of 6N hydrochloric acid and heat under reflux for 1 hour.The reaction mixture is allowed to cool, washed with ether, adjusted to pH 3.0 with 6N sodium hydroxide, and extracted with methylene chloride.
抽出液を硫酸ナトリウムで乾燥し、溶媒を留去して、5
−メルカプトキノリンの粗生成物35mg(収率57.
6%)を得る。これを精製することなく次の反応に用い
た。7β−[2−(2−トリチルアミノチアゾール−4
−イル)−(Z)−2−メトキシイミノアセトアミド]
−3−ヨードメチル−3−セフェム−4−カルボン酸ベ
ンズヒドリルエステル200[Ilg(0,21mmo
l)をIll、N−ジメチルホルムアミド2mi!に溶
かした溶液を、前記の粗5−メルカブトキノリンに加え
、室温で15分間攪拌した後、さらにヨウ化メチル2d
を加え、さらに同温度で3時間攪拌する。溶媒を留去し
た後、残渣を塩化メチレン1mg及びアニソール0.2
+njl!に溶かし、水冷下トリフルオロ酢酸1mQを
加え、室温で1時間攪拌する。溶媒を留去した後、残渣
にイソプロピルエーテルを加え、標記化合物のトリフル
オロ酢酸塩を粉末として得る。これを水に溶解し、炭酸
ナトリウム水溶液でpH6,5に合わせ、逆相カラムク
ロマトグラフィー(ケムコLC−SORB 、 5P−
B−ODS、20%メタノール水溶液で溶出)で精製し
、凍結乾燥して、標記化合物27a+g(収率22%)
を得る。The extract was dried over sodium sulfate, the solvent was distilled off, and 5
- 35 mg of crude mercaptoquinoline (yield 57.
6%). This was used in the next reaction without purification. 7β-[2-(2-tritylaminothiazole-4
-yl)-(Z)-2-methoxyiminoacetamide]
-3-iodomethyl-3-cephem-4-carboxylic acid benzhydryl ester 200 [Ilg (0,21 mmo
l) to Ill, N-dimethylformamide 2mi! The solution dissolved in
and further stirred at the same temperature for 3 hours. After distilling off the solvent, the residue was diluted with 1 mg of methylene chloride and 0.2 mg of anisole.
+njl! 1 mQ of trifluoroacetic acid was added under water cooling, and the mixture was stirred at room temperature for 1 hour. After distilling off the solvent, isopropyl ether is added to the residue to obtain the trifluoroacetate of the title compound as a powder. This was dissolved in water, adjusted to pH 6.5 with an aqueous sodium carbonate solution, and subjected to reverse phase column chromatography (Chemco LC-SORB, 5P-
B-ODS, eluted with 20% methanol aqueous solution) and lyophilized to give the title compound 27a+g (yield 22%)
get.
m p : 130〜140℃(分解)I R(KBr
)cffl :3400,1765,1670,160
5.153ONMR(DMSO−d、)δ:3.84(
3Ls)、4.25(II(、d。m p: 130-140°C (decomposition) I R (KBr
)cffl:3400,1765,1670,160
5.153ONMR(DMSO-d,)δ:3.84(
3Ls), 4.25(II(,d.
J=13Hz)、4.60(11(、d、J=13Hz
)、4.62(3H,s>。J=13Hz), 4.60(11(,d, J=13Hz
), 4.62 (3H,s>.
4.95(LH,d、J=4Hz)、5.45(IH,
m)、6.76(11(、s)。4.95 (LH, d, J=4Hz), 5.45 (IH,
m), 6.76 (11(, s).
7.26(2H,bs)、8.0−8.4(4H,m)
、9.50(2H,m)実施例10
7β−[2−(2−アミノチアゾール−4−イル)−(
Z)−2−(1−力ルボキシ−1−メチルエトキシイミ
ノ)アセトアミトコ−3−(1−メチルキノリニウム−
5−イル)チオメチル−3−セフェム−4−カルボキシ
レートナトリウム
実施例9と同様の方法で合成した。7.26 (2H, bs), 8.0-8.4 (4H, m)
, 9.50 (2H, m) Example 10 7β-[2-(2-aminothiazol-4-yl)-(
Z)-2-(1-ruboxy-1-methylethoxyimino)acetamitoco-3-(1-methylquinolinium-
Sodium 5-yl)thiomethyl-3-cephem-4-carboxylate was synthesized in the same manner as in Example 9.
m p : 130〜140℃(分解)IR(にBr)
ai :3400,1760,1600,1530,1
400,136ONMR(DMSO−d、)δ:1.3
8(3)1.s)、1.45(311,s)4.22(
IH,d、JJ2Hz)、4.35(IH,d、J=1
2Hz)、4.64(3H,s)、4.92(1)1.
d、J=4Hz)、5.62(II(、dd、J=43
8Hz)、6.72(IH,s)、7.20(2H,b
s)、8.0−8.4(4H,m)。m p: 130-140°C (decomposition) IR (Br)
ai: 3400, 1760, 1600, 1530, 1
400,136ONMR (DMSO-d,) δ: 1.3
8(3)1. s), 1.45 (311, s) 4.22 (
IH, d, JJ2Hz), 4.35 (IH, d, J=1
2Hz), 4.64 (3H, s), 4.92 (1) 1.
d, J=4Hz), 5.62(II(, dd, J=43
8Hz), 6.72 (IH, s), 7.20 (2H, b
s), 8.0-8.4 (4H, m).
9.45(IH,m)、9.62(LH,m)参考例1
N−メチルキノリン−4−チオン
N−メチル−4−キノロン6.37 g (40I+1
mol)をピリジン80威に溶かし、三硫化リン8.9
g (40mmol)を加え、攪拌下1時間加熱還流
する。溶媒を留去した後、残渣に酢酸エチル400d、
テトラヒドロフラン400m1!及び水200m2を加
え、有礪層を分取し、希塩酸次いで飽和食塩水で洗う6
無水硫酸マグネシウムで乾燥した後、溶媒を留去し、残
渣をメタノールから結晶化して標記化合物4.63 g
(収率66%)を得る。9.45 (IH, m), 9.62 (LH, m) Reference example 1 N-methylquinoline-4-thione N-methyl-4-quinolone 6.37 g (40I+1
Dissolve 8.9 mol of pyridine in 8.9 mol of phosphorus trisulfide.
g (40 mmol) and heated under reflux for 1 hour while stirring. After distilling off the solvent, 400 d of ethyl acetate was added to the residue.
400ml of tetrahydrofuran! Add 200 m2 of water, separate the solid layer, and wash with dilute hydrochloric acid and then saturated saline.
After drying over anhydrous magnesium sulfate, the solvent was distilled off and the residue was crystallized from methanol to yield 4.63 g of the title compound.
(yield 66%).
I R(KBr)ci71:1650,1535,15
20,1370.1160UVλ:: 226nm(t
=34,000)、252na+(t =6,800
) 。IR(KBr)ci71:1650,1535,15
20,1370.1160UVλ:: 226nm(t
=34,000), 252na+(t =6,800
).
272nm(t =7,500)、404nm(t w
t23,700)N M R(CDC1,)δ:3.9
(3H,s)、7.32(Ill、t、J=4Hz)7
.4−7.6(2H,m)、7.7(1B、s+)、9
.02(IH,d、J=8Hz)参考例2
N−(2−フルオロエチル)キノリン−4−チオン(A
)4−ヒドロキシキノリン2.18 g (15mio
l)をN、N−ジメチルホルムアミド45+dに溶かし
、50%油性水素化ナトリウム1.08 g (22,
5mmol )を加え、60℃に15分間加熱攪拌する
。放冷後1−ブロモー2−フルオロエタン1.68d(
22,5a+mol)を加え、室温で1.5時間攪拌す
る。溶媒を留去した後、残渣をシリカゲルカラムクロマ
トグラフィー(ワコーゲルC−300。272 nm (t = 7,500), 404 nm (tw
t23,700)NMR(CDC1,)δ:3.9
(3H, s), 7.32 (Ill, t, J = 4Hz) 7
.. 4-7.6 (2H, m), 7.7 (1B, s+), 9
.. 02 (IH, d, J=8Hz) Reference Example 2 N-(2-fluoroethyl)quinoline-4-thione (A
) 4-hydroxyquinoline 2.18 g (15mio
l) in 45+d of N,N-dimethylformamide and 1.08 g of 50% oily sodium hydride (22,
5 mmol) and stirred while heating at 60°C for 15 minutes. After cooling, 1.68 d of 1-bromo-2-fluoroethane (
22.5a+mol) and stirred at room temperature for 1.5 hours. After distilling off the solvent, the residue was subjected to silica gel column chromatography (Wakogel C-300).
1〜3%メタノール−クロロホルムで溶出)で精製し、
N−(2−フルオロエチル)−4−キノロン1.27g
(収率44.3%)を得る。eluted with 1-3% methanol-chloroform),
N-(2-fluoroethyl)-4-quinolone 1.27g
(yield 44.3%).
r R(KBr)cffl :3400.1630,1
590,1490,1230.1030UV λ’:
: : 236nm(t =20,900)、32
2r+m(E =14,200)335nlIl(E:
15,800)
N M R(CDC1,”)δ:4.44(2H,d5
J=24 & 4土)。r R(KBr)cffl :3400.1630,1
590,1490,1230.1030UV λ':
: : 236 nm (t = 20,900), 32
2r+m (E = 14,200) 335nlIl (E:
15,800) NMR(CDC1,”)δ:4.44(2H,d5
J=24 & 4 Sat).
4.81(2H,dt、J=47 & 4m)、6.3
0(18,d、J=7比)。4.81 (2H, dt, J=47 & 4m), 6.3
0 (18, d, J=7 ratio).
7.38(IH,d、J=7土)、7.42(IH,t
、J=7比)、7.57(1B、d、J=7Hz)、7
.70(xH,t、J=7Hz)、8.50(18,d
。7.38 (IH, d, J = 7 soil), 7.42 (IH, t
, J=7 ratio), 7.57 (1B, d, J=7Hz), 7
.. 70 (xH, t, J = 7Hz), 8.50 (18, d
.
J=7比)
(B) (A)で得られた、N−(2−フルオロエチル
)−4−キノロン1.15 g (6mn+ol)をピ
リジン10dに溶かし、三硫化リン1.33 g (6
a+mol )を加え、60℃に1時間加熱攪拌する。J=7 ratio) (B) 1.15 g (6 mn+ol) of N-(2-fluoroethyl)-4-quinolone obtained in (A) was dissolved in 10 d of pyridine, and 1.33 g (6 mn+ol) of phosphorus trisulfide was dissolved in 10 d of pyridine.
a+mol) and stirred while heating at 60°C for 1 hour.
溶媒を留去し、残渣をクロロホルム150−に溶かし、
水、次いで飽和食塩水で洗う。The solvent was distilled off, the residue was dissolved in chloroform 150-
Wash with water and then saturated saline.
無水硫酸マグネシウムで乾燥し、溶媒を留去し、残渣を
酢酸エチルでトリチュレートして標記化合物1.15g
(収率92.5%)を得る。Dry over anhydrous magnesium sulfate, remove the solvent, and triturate the residue with ethyl acetate to obtain 1.15 g of the title compound.
(yield 92.5%).
I R(KBr)a(:1600,1590,1530
,1440,1370,1160UVλ’:: : 2
27nm(E =32,700)、406nm(ε=2
3,400)参考例3
N−ジフェニルメトキシカルボニルメチルキノリン−4
−チオン
(A)4−ヒドロキシキノリン726mg(5mIno
l)をN、N−ジメチルホルムアミド10屁に溶かし、
50%油性水素化ナトリウム360mg (7,5mn
ol)を加え、60℃に15分加熱攪拌する。放冷後、
モノクロル酢酸ベンズヒドリルエステル1.96 g
(7,5mmol)とヨウ化カリウム1.66 g (
lornrnol’)を加え、60℃に1時間攪拌する
。I R(KBr)a(:1600,1590,1530
,1440,1370,1160UVλ' : : : 2
27 nm (E = 32,700), 406 nm (ε = 2
3,400) Reference Example 3 N-diphenylmethoxycarbonylmethylquinoline-4
-thione (A) 4-hydroxyquinoline 726 mg (5ml
l) in 10 volumes of N,N-dimethylformamide,
50% oily sodium hydride 360mg (7.5mn
ol) and stirred while heating at 60°C for 15 minutes. After cooling,
Monochloroacetic acid benzhydryl ester 1.96 g
(7.5 mmol) and potassium iodide 1.66 g (
lornrnol') and stirred at 60°C for 1 hour.
溶媒を留去した後、残渣をシリカゲルカラムクロマトグ
ラフィー(フコ−ゲルC−300,0〜5%メタノール
−クロロホルムで溶出)で精製し、N−ジフェニルメト
キシカルボニルメチル−4−キノロン1.55 g (
収率83.9%)を得る。After evaporating the solvent, the residue was purified by silica gel column chromatography (Fuco-gel C-300, eluted with 0-5% methanol-chloroform) to obtain 1.55 g of N-diphenylmethoxycarbonylmethyl-4-quinolone (
Yield: 83.9%).
I R(KBr)cffl :1750,1620,1
590,1485,1220.119ON M R(C
DCI、 )δ:4.87(2)1.s)、6.35(
11(、d、J=8Hz)6.94(IH,s)、7.
1−7.6(15H,!l)、8.49(IH,d、に
8比)
(B) (A)で得られた。N−ジフェニルメトキシカ
ルボニルメチル−4−キノロン1.48g (4mmo
l)をピリジン10蛇に溶かし、三硫化リン0.89
g (4mol)を加え、60℃で1時間加熱攪拌する
。溶媒を留去し。IR(KBr)cffl :1750,1620,1
590,1485,1220.119ON M R(C
DCI, ) δ: 4.87 (2) 1. s), 6.35(
11 (, d, J=8Hz) 6.94 (IH, s), 7.
1-7.6 (15H, !l), 8.49 (IH, d, 8 ratio) (B) Obtained in (A). N-diphenylmethoxycarbonylmethyl-4-quinolone 1.48g (4mmo
l) in 10 parts of pyridine, 0.89 parts of phosphorus trisulfide
g (4 mol) was added, and the mixture was heated and stirred at 60°C for 1 hour. Distill the solvent.
残渣に酢酸エチル500d、 N、N−ジメチルホルム
アミド10屁及び水50mff1を加え、有機層を分取
する。To the residue were added 500 d of ethyl acetate, 10 farts of N,N-dimethylformamide and 50 mff 1 of water, and the organic layer was separated.
有機層を水次いで飽和食塩水で洗った後、無水硫酸マグ
ネシウムで乾燥し、溶媒を留去する。残渣を酢酸エチル
でトリチュレートして標記化合物を0.93g(収率6
0.3%)を得る。The organic layer was washed with water and then with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off. The residue was triturated with ethyl acetate to give 0.93 g of the title compound (yield: 6
0.3%).
I R(KBr)cffl :1750,1590.1
160UVλ’:: : 224nm(t =33,6
00)、408nc(E =24,900)N M R
(CDCIs)δ:4.94<2H,s)、6.94(
1)f、s)、7.2−7.6(15H,m)、9.0
5(IH,d、J=8Hz)参考例4
6.7−ジヒドロキシ−N−メチルキノリン−4−チオ
ン(A)ジャーナル・オブ・アメリカン・ケミカル・ソ
サイエティ(J、 Am、 Chem、 Soc、)、
第68巻、1264頁(1964年)に記載の方法で合
成した、6,7−シメトキシー4−キノ−リノール3.
08 g (15mmol )をN、N−ジメチルホル
ムアミド60或に溶かし、ヨウ化メチル1.4IIIQ
(22,5mmol )及び炭酸カリウム3.1 g
(22,5mmol)を加え、40℃で4時間攪拌す
る。溶媒を留去し、残渣をシリカゲルカラムクロマトグ
ラフィー(ワコーゲルc−300,0〜3%メタノール
−ジクロルメタンで溶出)でM製し、6.7−ジメトキ
シ−N−メチル−4−キノロン1.97g(収率59.
9%)を得る。IR(KBr)cffl :1750,1590.1
160UVλ':: 224nm (t = 33,6
00), 408 nc (E = 24,900) N M R
(CDCIs) δ: 4.94<2H,s), 6.94(
1) f, s), 7.2-7.6 (15H, m), 9.0
5 (IH, d, J = 8 Hz) Reference example 4 6.7-dihydroxy-N-methylquinoline-4-thione (A) Journal of the American Chemical Society (J, Am, Chem, Soc,),
6,7-Simethoxy-4-quinolinol 3. synthesized by the method described in Vol. 68, p. 1264 (1964).
Dissolve 08 g (15 mmol) in 60% N,N-dimethylformamide to obtain 1.4IIIQ methyl iodide.
(22,5 mmol) and potassium carbonate 3.1 g
(22.5 mmol) and stirred at 40°C for 4 hours. The solvent was distilled off, and the residue was purified by silica gel column chromatography (Wako Gel C-300, eluted with 0-3% methanol-dichloromethane) to obtain 1.97 g of 6.7-dimethoxy-N-methyl-4-quinolone ( Yield: 59.
9%).
I R(KBr)ai? :3400,1620,15
50,1490.1270UVλ’:: : 249n
m(i =28,100)、324nm(F=io、3
oo)337nm(t =11,200)
N M R(DMSO−d、 ’)δ:3.82(3H
,S)、3.86(3H,S)。I R(KBr)ai? :3400,1620,15
50,1490.1270UVλ' : : : 249n
m (i = 28,100), 324 nm (F = io, 3
oo) 337 nm (t = 11,200) NMR(DMSO-d,') δ: 3.82 (3H
, S), 3.86 (3H, S).
3.96(3H,s)、5.96(18,d、J’8H
z)、7.03(Ill、s)+7.55(1)!、s
)、7.87(lH,d、J=8Hz )(B) (A
)で得られた、6,7−ジメトキシ−N−メチル−4−
キノロン1.32 g (6mmol)を47%臭化水
素酸13−に溶かし、−夜前熱還流する。溶媒を留去し
、残渣をアセトンで洗って、6,7−ジヒドロキシ−N
−メチル−4−キノロン臭化水素酸塩1.3g(収率7
9.6%)を得る。3.96 (3H, s), 5.96 (18, d, J'8H
z), 7.03 (Ill, s) + 7.55 (1)! ,s
), 7.87 (lH, d, J=8Hz) (B) (A
), 6,7-dimethoxy-N-methyl-4-
1.32 g (6 mmol) of quinolone was dissolved in 47% hydrobromic acid 13- and heated to reflux overnight. The solvent was distilled off, the residue was washed with acetone, and the 6,7-dihydroxy-N
-Methyl-4-quinolone hydrobromide 1.3 g (yield 7
9.6%).
I R(KBr)aW :3400,3150,163
0,1580,1550,1510゜30O
N M R(DMSO−d、 )δ:4.22(38,
s)、6.99(IH,d、J=7Hz)、7.38(
LH,s)、7.61(IH,s)、8.70(LH,
d、Jニア比)
(C) (B)で得られた。6,7−ジヒドロキシ−N
−メチル−4−キノロン臭化水素酸塩1.22 g (
4,5fflfflol)をピリジン7dに溶かし、三
硫化リン1 g (4,5mmol)を加え、60℃に
1時間加熱攪拌する。溶媒を留去し残渣を水次いでメタ
ノールで洗うことにより、標記化合物を0.5 g (
収率53.6%)得る。IR(KBr)aW :3400,3150,163
0,1580,1550,1510°30O NMR(DMSO-d, )δ:4.22(38,
s), 6.99 (IH, d, J=7Hz), 7.38 (
LH, s), 7.61 (IH, s), 8.70 (LH,
d, J near ratio) (C) Obtained in (B). 6,7-dihydroxy-N
-Methyl-4-quinolone hydrobromide 1.22 g (
4.5fflfflol) was dissolved in 7d of pyridine, 1 g (4.5 mmol) of phosphorus trisulfide was added, and the mixture was heated and stirred at 60° C. for 1 hour. The solvent was distilled off and the residue was washed with water and then methanol to obtain 0.5 g of the title compound (
Yield: 53.6%).
I R(KBr)a[:3400,1630,1610
,1480,1460,1265UVλ’:: : 2
34nm(i =19,000)、331na+(E
=5,800)。I R(KBr)a[:3400,1630,1610
,1480,1460,1265UVλ' : : : 2
34nm (i = 19,000), 331na+(E
= 5,800).
402nm(t 1113,900)
N M R(DMSO−d、 )δ:3.92(3B、
s)、7.22(lH,d、Jニア比)、7.43(I
H,s’) 、7.84(ILd、Jニア比)、8.2
4(II(。402 nm (t 1113,900) NMR (DMSO-d, ) δ: 3.92 (3B,
s), 7.22 (lH, d, J near ratio), 7.43 (I
H, s'), 7.84 (ILd, J near ratio), 8.2
4(II(.
S)
且ユ匹隻員
本発明化合物は、優れた抗菌活性を示すことから1人間
を含む哺乳動物の細菌感染症の治療剤として有用である
。S) Since the compound of the present invention exhibits excellent antibacterial activity, it is useful as a therapeutic agent for bacterial infections in mammals including humans.
Claims (3)
アルキル基、置換されていてもよいシクロアルキル基、
置換されていてもよい低級アルケニル基、置換されてい
てもよい低級アルキニル基、置換されていてもよいアリ
ール基又は置換されていてもよいアラルキル基を、R^
2は置換されていてもよい低級アルキル基、置換されて
いてもよいシクロアルキル基、置換されていてもよい低
級アルケニル基又は置換されていてもよい低級アルキニ
ル基を、R^3、R^4及びR^5は同一又は異なって
いてもよく、水素原子、ハロゲン原子、置換されていて
もよい低級アルキル基、水酸基、低級アルコキシ基、低
級アルカノイルオキシ基、アミノ基、低級アルキルアミ
ノ基、低級アルカノイルアミノ基、カルボキシル基、低
級アルコキシカルボニル基、置換されていてもよいカル
バモイル基、スルホ基、スルファモイル基、低級アルカ
ノイル基又はニトロ基をそれぞれ示す]で表される化合
物又はその無毒性塩。(1) General formula ▲ Numerical formula, chemical formula, table, etc. ▼ [I] [In the formula, R^1 is a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group,
An optionally substituted lower alkenyl group, an optionally substituted lower alkynyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group, R^
2 is an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group, or an optionally substituted lower alkynyl group, R^3, R^4 and R^5 may be the same or different, and include a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, an amino group, a lower alkylamino group, and a lower alkanoyl group. an amino group, a carboxyl group, a lower alkoxycarbonyl group, an optionally substituted carbamoyl group, a sulfo group, a sulfamoyl group, a lower alkanoyl group, or a nitro group, or a non-toxic salt thereof.
[ I ]のR^1又はR^1の官能基が保護された置換
基を、R^6は水素原子又はアミノ基の保護基を、R^
7は水素原子又はカルボキシル基の保護基を、Xはハロ
ゲン原子又はアセトキシ基をそれぞれ示す]で表される
化合物又はその塩を、 一般式[III] ▲数式、化学式、表等があります▼[III] [式中、R^2^0は水素原子又は後記の一般式[ I
]のR^2若しくはR^2の官能基が保護された置換基
を、R^3^0、R^4^0及びR^5^0はそれぞれ
後記の一般式[ I ]のR^3、R^4及びR^5、若
しくはR^3、R^4及びR^5の官能基が保護された
置換基をそれぞれ示す]で表される化合物と反応させ、
次いで所望により、 (i)キノリン環のN−アルキル化を行う工程(ii)
保護基を除去する工程 (iii)無毒性塩に変換する工程 以上の工程を1ないしそれ以上行うことを特徴とする、 一般式 ▲数式、化学式、表等があります▼[ I ] [式中、R^1は水素原子、置換されていてもよい低級
アルキル基、置換されていてもよいシクロアルキル基、
置換されていてもよい低級アルケニル基、置換されてい
てもよい低級アルキニル基、置換されていてもよいアリ
ール基又は置換されていてもよいアラルキル基を、R^
2は置換されていてもよい低級アルキル基、置換されて
いてもよいシクロアルキル基、置換されていてもよい低
級アルケニル基又は置換されていてもよい低級アルキニ
ル基を、R^3、R^4及びR^5は同一又は異なって
いてもよく、水素原子、ハロゲン原子、置換されていて
もよい低級アルキル基、水酸基、低級アルコキシ基、低
級アルカノイルオキシ基、アミノ基、低級アルキルアミ
ノ基、低級アルカノイルアミノ基、カルボキシル基、低
級アルコキシカルボニル基、置換されていてもよいカル
バモイル基、スルホ基、スルファモイル基、低級アルカ
ノイル基又はニトロ基をそれぞれ示す]で表される化合
物又はその無毒性塩の製法。(2) General formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ [II] [In the formula, R^1^0 is a protecting group for the hydroxyl group or a functional group of R^1 or R^1 in the general formula [I] described below. The group is a protected substituent, R^6 is a hydrogen atom or an amino group protecting group, R^
7 represents a hydrogen atom or a protecting group for a carboxyl group, X represents a halogen atom or an acetoxy group, respectively] or its salt is represented by the general formula [III] ▲There are mathematical formulas, chemical formulas, tables, etc.▼ [III ] [In the formula, R^2^0 is a hydrogen atom or the general formula [ I
] R^2 or a substituent in which the functional group of R^2 is protected, R^3^0, R^4^0 and R^5^0 are respectively R^3 of the general formula [I] below , R^4 and R^5, or the functional groups of R^3, R^4 and R^5 each represent a protected substituent],
Then, if desired, (i) step (ii) of N-alkylating the quinoline ring.
General formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ [I] [In the formula, R^1 is a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group,
An optionally substituted lower alkenyl group, an optionally substituted lower alkynyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group, R^
2 is an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group, or an optionally substituted lower alkynyl group, R^3, R^4 and R^5 may be the same or different, and include a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, an amino group, a lower alkylamino group, and a lower alkanoyl group. A method for producing a compound represented by an amino group, a carboxyl group, a lower alkoxycarbonyl group, an optionally substituted carbamoyl group, a sulfo group, a sulfamoyl group, a lower alkanoyl group, or a nitro group, or a non-toxic salt thereof.
アルキル基、置換されていてもよいシクロアルキル基、
置換されていてもよい低級アルケニル基、置換されてい
てもよい低級アルキニル基、置換されていてもよいアリ
ール基又は置換されていてもよいアラルキル基を、R^
2は置換されていてもよい低級アルキル基、置換されて
いてもよいシクロアルキル基、置換されていてもよい低
級アルケニル基又は置換されていてもよい低級アルキニ
ル基を、R^3、R^4及びR^5は同一又は異なって
いてもよく、水素原子、ハロゲン原子、置換されていて
もよい低級アルキル基、水酸基、低級アルコキシ基、低
級アルカノイルオキシ基、アミノ基、低級アルキルアミ
ノ基、低級アルカノイルアミノ基、カルボキシル基、低
級アルコキシカルボニル基、置換されていてもよいカル
バモイル基、スルホ基、スルファモイル基、低級アルカ
ノイル基又はニトロ基をそれぞれ示す]で表される化合
物又はその無毒性塩を有効成分とする抗菌剤。(3) General formula ▲ Numerical formula, chemical formula, table, etc. ▼ [I] [In the formula, R^1 is a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group,
An optionally substituted lower alkenyl group, an optionally substituted lower alkynyl group, an optionally substituted aryl group, or an optionally substituted aralkyl group, R^
2 is an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted lower alkenyl group, or an optionally substituted lower alkynyl group, R^3, R^4 and R^5 may be the same or different, and include a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, an amino group, a lower alkylamino group, and a lower alkanoyl group. An active ingredient is a compound represented by an amino group, a carboxyl group, a lower alkoxycarbonyl group, an optionally substituted carbamoyl group, a sulfo group, a sulfamoyl group, a lower alkanoyl group, or a nitro group, or a non-toxic salt thereof. antibacterial agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63086036A JPH01258684A (en) | 1988-04-07 | 1988-04-07 | 3-substituted quinolinium thiomethylcephalosporin derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63086036A JPH01258684A (en) | 1988-04-07 | 1988-04-07 | 3-substituted quinolinium thiomethylcephalosporin derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01258684A true JPH01258684A (en) | 1989-10-16 |
Family
ID=13875443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63086036A Pending JPH01258684A (en) | 1988-04-07 | 1988-04-07 | 3-substituted quinolinium thiomethylcephalosporin derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01258684A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180719A (en) * | 1988-10-24 | 1993-01-19 | Norwich Eaton Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactam esters |
WO1993015084A1 (en) * | 1992-01-23 | 1993-08-05 | Il-Dong Pharm. Co., Ltd. | Novel cephalosporin compounds |
US5328908A (en) * | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
US5387748A (en) * | 1988-10-24 | 1995-02-07 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial dithiocarbamoyl quinolones |
US5434147A (en) * | 1988-10-24 | 1995-07-18 | Proctor & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactam esters |
US5491139A (en) * | 1988-10-24 | 1996-02-13 | The Procter & Gamble Company | Antimicrobial quinolonyl lactams |
US5530116A (en) * | 1990-04-18 | 1996-06-25 | The Procter & Gamble Company | Antimicrobial quinolonyl lactams |
US5637580A (en) * | 1988-10-24 | 1997-06-10 | The Procter & Gamble Company | Antimicrobial penem-quinolones |
WO2013002215A1 (en) * | 2011-06-27 | 2013-01-03 | 塩野義製薬株式会社 | Cephem compound having pyridinium group |
-
1988
- 1988-04-07 JP JP63086036A patent/JPH01258684A/en active Pending
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637580A (en) * | 1988-10-24 | 1997-06-10 | The Procter & Gamble Company | Antimicrobial penem-quinolones |
US5434147A (en) * | 1988-10-24 | 1995-07-18 | Proctor & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactam esters |
US5180719A (en) * | 1988-10-24 | 1993-01-19 | Norwich Eaton Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactam esters |
US5387748A (en) * | 1988-10-24 | 1995-02-07 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial dithiocarbamoyl quinolones |
US5646139A (en) * | 1988-10-24 | 1997-07-08 | The Procter & Gamble Company | Antimicrobial carbapenem quinolones |
US5491139A (en) * | 1988-10-24 | 1996-02-13 | The Procter & Gamble Company | Antimicrobial quinolonyl lactams |
US5672600A (en) * | 1988-10-24 | 1997-09-30 | The Procter & Gamble Company | Antimicrobial dithiocarbamoyl quinolones |
US5648346A (en) * | 1988-10-24 | 1997-07-15 | The Procter & Gamble Company | Antimicrobial carbacephem-quinolones |
US5328908A (en) * | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
US5656623A (en) * | 1988-10-24 | 1997-08-12 | The Procter & Gamble Company | Antimicrobial lactam-quinolones |
US5631256A (en) * | 1988-10-24 | 1997-05-20 | The Procter & Gamble Company | Antimicrobial quinolone thioureas |
US5530116A (en) * | 1990-04-18 | 1996-06-25 | The Procter & Gamble Company | Antimicrobial quinolonyl lactams |
WO1993015084A1 (en) * | 1992-01-23 | 1993-08-05 | Il-Dong Pharm. Co., Ltd. | Novel cephalosporin compounds |
WO2013002215A1 (en) * | 2011-06-27 | 2013-01-03 | 塩野義製薬株式会社 | Cephem compound having pyridinium group |
CN103619853A (en) * | 2011-06-27 | 2014-03-05 | 盐野义制药株式会社 | Cephem compound having pyridinium group |
JPWO2013002215A1 (en) * | 2011-06-27 | 2015-02-23 | 塩野義製薬株式会社 | Cephem compound having pyridinium group |
US9242999B2 (en) | 2011-06-27 | 2016-01-26 | Shionogi & Co., Ltd. | Cephem compound having pyridinium group |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI65623C (en) | EXAMINATION OF ANTIBIOTICS ACTIVE (6R 7R) -3-CARBAMOYLOXIMETHYL-7- (2- (FUR-2-YL) -2-METHOXIMINOACETAMIDO) -CEF-3-EM-4-CARBOXYL SYRICATE | |
JPH01258684A (en) | 3-substituted quinolinium thiomethylcephalosporin derivative | |
JP2867192B2 (en) | 7-acyl-3-substituted carbamoyloxycephem compounds and method for producing the same | |
CA2190245A1 (en) | Cephalosporin compounds and processes for the preparation thereof | |
EP0280240B1 (en) | Cephalosporin derivatives, process for their preparation and antibacterial agents | |
JPS62158289A (en) | Novel cephalosporin derivative | |
JPS62209082A (en) | Cephalosporin derivative | |
JPS6097984A (en) | Cephem derivative, manufacture and medicinal composition | |
JP3743680B2 (en) | Novel cephem compound, production method thereof and antibacterial agent | |
JP3140525B2 (en) | Novel cephalosporin derivatives and their salts | |
JPS617280A (en) | Cephalosporin derivative | |
JPH04266889A (en) | Antibiotic c-3 cathecol-substituted cephalosporin compound, composition and its use | |
JP3061911B2 (en) | Novel cephem compound, its production method and antibacterial agent | |
JP2617618B2 (en) | Cefarosporin derivative | |
JPH01242589A (en) | Cephem compound | |
JPH04261183A (en) | Antibiotic c-3dihydroxyphenyl-substituted cephalosporin compound, composition and their use | |
JPS62226986A (en) | Novel cephalosporin derivative | |
JP3005273B2 (en) | Thiazolylacetamide-3-cephem derivatives | |
JP2566680B2 (en) | Vinyl thioacetic acid derivative | |
JPS61130293A (en) | Fluorinated alkylcephalosporin compound | |
JPH0249791A (en) | 3-(1-benzylpyridinium)thiomethylcephalosporin derivative | |
JPH0228186A (en) | Cephalosporin derivative | |
EP0300423A2 (en) | Cephalosporin compound, method of its production and composition for prevention and treatment of bacterial infectious diseases | |
JPH0269485A (en) | Cephalosporin derivative | |
JPS62289585A (en) | Novel cephalosporin derivative |